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Abstract 
 
KRAS-driven cancers are notoriously difficult to treat due to poor pharmacodynamics of 
downstream inhibitors and resistance to anti-EGFR drugs. IMP-1 is a post-transcriptional regulator 
of KRAS mRNA. As a novel therapeutic approach, the targeting of the IMP-1-KRAS mRNA 
complex with a spiropyrrolizidine derivative (UNBC152), was studied. LC-MS analysis of 
UNBC152 indicated presence of impurities. The purpose of this study was to synthesize UNBC152 
and determine the responsible bioactive molecule within the impurities. LC-MS and TLC 
suggested the presence of a bioactive [3+3] cycloaddition side product (SPOPP) in UNBC152. 
SPOPP suppressed KRAS expression in human colorectal cancer cells. Fluorescence polarization 
determined that SPOPP did not impact the IMP-1-KRAS mRNA interaction. SPOPP induced 
G2/M cell cycle arrest as shown by flow cytometry. MTT assay confirmed the SPOPP-induced 
growth inhibition in SW480 (IC50 = 4.17 μM) and HT29 (IC50 = 6.76 μM). These findings represent 
a first reporting on the bioactivity of SPOPP.  
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Chapter 1 
Introduction 
1.1. Oncogenes 
The discovery of oncogenes began in the early 1900s with a researcher named Peyton 
Rous.1,2 During his studies on the domestic fowl, he found that a tumor extract, when injected into 
a healthy chicken, will initiate tumorigenesis.1 The extract was found to contain a virus and was 
later named the Rous Sarcoma Virus (RSV). Discovery of the RSV viral gene (v-src) was 
accomplished with a combination of oligonucleotide finger printing and sucrose gradient 
centrifugation.3 The discovery led to the idea of possible non-viral genes which can promote 
tumorigenesis. Mike Bishop and Harold Varmus created a v-src complementary DNA (cDNA) 
probe through reverse transcription to find the endogenous avian src gene.4 Hybridization 
experiments using v-src cDNA and avian DNA led to the discovery of the sought after src gene; 
this led to the term proto-oncogene. From the discovery, research for additional proto-oncogenes 
in cancer proceeded.5 
Conversion of proto-oncogenes to oncogenes can occur from one of four main events: point 
mutation, upregulation, chromosome translocation or gene amplification.6 Mutations include 
single nucleotide replacement, nucleotide deletion(s), frameshift mutation, and nucleotide 
insertion. Following ribosomal translation of the mutated gene, the newly synthesized protein has 
altered structural conformation. Structural changes range from complete mis-folding of the protein 
to slight steric hindrance of an active site. The end result is either altered activity or altered post 
transcriptional regulation. In both cases, cellular homeostasis is imbalanced, leading to deleterious 
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effects. Upregulation results in the increased production of protein; this often occurs from 
malfunctioning transcriptional regulators or an increase in messenger RNA stability. 
Chromosomal translocation often leads to the creation of fusion genes. Fusion gene products alter 
the cellular interactions of their respective counterparts.6 Gene amplification results in multiple 
copies of the oncogene. 
Identification of oncogenes are important since the products are often involved in 
regulation of the cell cycle or apoptosis.6 Several well-known oncogenes include the following: 
Myc, epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), and Ras. The 
method in which a proto-oncogene is activated will determine its cellular effect.  Myc is a 
transcriptional regulator and is located on position 24 on the long arm of the chromosome 8 (8q24) 
for humans. Translocation of Myc to gene positions 14q, 22q and 2p causes the gene to be 
positioned near an enhancer leading to Burkitt’s lymphoma. In EGFR mutations, the ligand 
binding domain is often deleted which leads to a perpetual on state (constitutive signaling). EGFR 
and related proteins are found in breast and lung cancer. PI3K is a tyrosine kinase and activates 
Akt in a signal transduction pathway involved with cell growth and survival.6 Ras is a 
transmembrane protein which, upon activation, signals the canonical mitogen activated protein 
kinase (MAPK) and PI3K pathways, leading to growth and differentiation of cells.7 More 
information on Ras will be discussed in section 1.6. Given the diversity of oncogenes and the 
interplay with various signaling pathways, it is difficult to determine a singular target for anti-
cancer therapy. 
1.2. RNA Regulation 
Precise spatiotemporal regulation of RNA is the main factor which allows a cell to rapidly 
and efficiently adjust to cellular demands.8 Steady state levels of RNA fluctuate depending on cell 
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type, cell cycle and potential exposure to negative stimuli, such as carcinogens and toxins. Other 
factors influencing steady state mRNA levels are pre-mRNA splicing, transcription rates, RNA 
degradation and interaction with microRNAs and RNA binding proteins.8  
Expression of RNA can be modulated by RNA interference (RNAi) molecules.9 A subset 
of RNAi, microRNA (miRNA), are produced from double stranded RNA after processing by the 
RNase III enzymes Dicer and Drosha. The miRNA is a short fragment of approximately 22 
nucleotides in length and associates with mRNA through Watson-Crick base pairing.10 If the 
miRNA is perfectly matched, the mRNA is degraded by the RNaseH enzyme named Argonaute 
which is located in the RNA-induced silencing complex (RISC).9 Alternatively, mismatched 
siRNA causes translational inhibition of the mRNA.  
RNA binding proteins (RBP) are one of the major post-transcriptional regulators of RNA11. 
RBPs aid in capping, translation, localization, turnover, splicing and various other processes 
relating to steady state levels of RNA. RBPs often contain RNA recognition motifs (RRM) and 
heterogeneous nuclear ribonucleoprotein (hnRNP) K Homology (KH) domains. The domains 
serve to bind RNA based on a sequence specific motif.  Currently there are 424 known RBPs with 
varying functionalities but interestingly, some of the prerequisite motifs for binding are not unique 
to each protein variant; this indicates that a singular RBP regulates more than one RNA species. 
Any perturbation in RBP levels can impact RNA regulation.11 A specific example would be the 
transcriptomic analysis performed by Voineagu et al. on autistic brains.12 Downregulation of the 
RBP, ataxin 2-binding protein 1 (A2BP1), led to 212 significant alternative splicing events. 
Numerous implicated exons from the alternative splicing were found to be involved in synaptic 
function of neuronal cells; thus there is a significant correlation between A2BP1 expression levels 
and regulation of synaptic events.12 In prostate cancer, the RBP named Sam68 is upregulated and 
4 
 
is correlated with neoplastic effects.13 Downregulation of Sam68 through RNA interference 
reduced the proliferation of the LNCaP prostate cancer cell line.13 RBP expression can vastly affect 
the post-transcriptional regulation of RNA targets.  Any dysregulation of RBP, such as a small 
expression fold change, may greatly impact RNA steady-state levels leading to a diseased state. 
1.3. IMP-1: Structure and Function 
The Insulin-like Growth Factor 2 mRNA-binding Protein 1 (IMP-1) was initially discovered 
through a UV cross-linking experiment.14 Through this process, the 75 kDa protein was chemically 
bound to the coding region determinant of the c-Myc transcript. At the time of discovery, IMP-1 
was suggested to protect the transcript from endoribonuclease attack.14 IMP-1is a member of a 
larger family of highly conserved RNA binding proteins called VICKZ (Vg1, RBP/Vera, IMP-
1,2,3, CRD-BP, KOC and ZBP-1).15 According to NCBI blast, the murine IMP-1 protein has a 
99% amino acid sequence identity to the human variant. As seen in Figure 1.3.1, IMP-1 contains 
two N-terminal RRMs and four KH domains which arrange in the following di-domains: RRM1-
RRM2, KH1-KH2 and KH3-KH4.16 The discrete di-domains are separated from each other 
through a long variable region.17  Within the di-domain pair, a shorter and more conserved spacer 
exists.17  
 
Figure 1.3.1. Schematic of wild-type coding region determinant binding protein (WT IMP-
1) displaying domains and associated nucleotide positions.16 
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RNA binding in IMP-1 occurs through the four KH domains.18 KH domains exist in two 
forms. Eukaryotes have the type I fold while prokaryotes have the type II fold. As seen in Figure 
1.3.2, type I and type II folds differ by the placement of β’ and α’ leading to differences in 
secondary structure. The KH domains in IMP-1 contain the type I fold. Binding of RNA occurs 
through the region between the left side (α1, GXXG, α2) and right side (β2 and a variable loop).18 
Contrary to traditional RRM domains, IMP-1 does not require the RRM1 or RRM2 to bind RNA.17   
 
Figure 1.3.2. Secondary structure differences of KH domain types. (A) Eukaryotic KH 
domain, (B) Prokaryotic KH domain.18  
 
 Further elucidation of the binding requirements was done in a mutational experiment by 
Barnes et al. in 2015.16 Since the GXXG motif was implicated in binding RNA, the first glycine 
(G) of the motif was mutated by site-directed mutagenesis into an aspartate (D) in order to abrogate 
binding. The single mutants, KH1, KH2, KH3 and KH4 were created. For example, the KH1 
mutant has the GXXG loop mutated to DXXG for the KH1 domain while the KH2, KH3 and KH4 
domains remain in its wildtype form. Dual domain mutants were also created such as KH1-2 and 
KH3-4. It was found that the single point mutants KH1, KH2, KH3 and KH4 had varying ability 
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to bind to both CD44 and c-Myc RNA. Interestingly the KH4 mutant had a higher affinity towards 
c-Myc RNA than CD44. Mutations in any two domains, however, abrogated binding completely. 
The KH3-4 di-mutant was the only exception to the finding; the dual mutation still resulted in 
binding. Given the variation in binding ability of the mutants towards the target RNA, it suggests 
that different domains are required for sequence specificity. Additionally, the data suggests that at 
least two domains are required for strong binding.16  
 Structural elucidation of IMP-1 has been historically challenging due to the flexible 
variable regions between the di-domain pairs. The only crystal structure solution of a VICKZ 
protein was a truncation of IMP-1 as solved by Chao, et al. in 2010 to a resolution of 2.75Å.19 
 
Figure 1.3.3. Crystal structure of truncated IMP-1. (A) KH3 and KH4 dimer. (B) 
Hydrophobic residues involved for dimerization.19 
 
Hydrophobic residues located on β1 and α3 of both KH3 and KH4 form electrostatic interactions 
leading to sequestering and the formation of the pseudo-dimer (Figure. 1.3.3B). Of note, the 
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GXXG motif between α1 and α2 of KH3 and KH4 lie in opposition to each other (Figure. 1.3.3A). 
Due to the orientation of both GXXG motifs, Chao, et al. hypothesized that the RNA substrate 
wraps around KH3 and KH4 in a 180° fashion. The minimum nucleotide requirement for 
specificity was also explored during their in vitro analysis of the KH3 and KH4 domains in ZBP1. 
Using the electrophoretic mobility shift assay, it was shown that the KH3 and KH4 domains 
displayed similar high affinity to the first 28 nucleotides of the zipcode as compared to the full-
length protein. A deletion of 2 to 4 nucleotides in the middle of the zipcode did not change the 
protein’s affinity. However, a deletion of 6 nucleotides led to a magnitude lower in affinity and a 
deletion of 8 nucleotides abrogated binding completely.19 The finding suggests the importance of 
nucleotide length for high affinity bipartite recognition by the KH3 and KH4 domains of VICKZ 
proteins. A minimum of 17 nucleotides are required to be energetically favorable for wrapping 
around the two domains. In reality, the in vivo affinity of VICKZ proteins to their substrates are 
vastly different due to substrates’ length being in the thousands of nucleotides. Binding affinity 
would then be enhanced by the presence of all 4 KH domains since the KH1 and KH2 domains 
acts as extra binding surfaces for electrostatic interactions with RNA. The RNA will then 
hypothetically loop around both di-domain pairs (KH3 and KH4; KH2 and KH1). The 
crystallization of the full protein is warranted for the elucidation of all binding surfaces and RNA 
orientation. An attempt to crystallize IMP-1, which consisted of KH1 to KH4 domains, was done 
by Mackedenski but unfortunately, the crystal twinned and could not be diffracted.20 
1.4. IMP-1: Role in Development and Oncogenesis  
IMP-1 is the first oncofetal RBP that was reported.21 Leeds et. al.  monitored IMP-1 
expression in rat liver tissue during the fetal and neonatal stage and found expression. However, 
the protein was not found to be expressed during the adult stage. To further clarify the role in 
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development, IMP-1 expression was also monitored in liver tissue following partial liver resection. 
Interestingly, IMP-1 expression was absent in the liver tissue. Analysis of the hepatoma cell lines, 
HepG2, HuH7 and Hep3B resulted in redetection of IMP-1; therefore IMP-1 is only found during 
early development and in cancer.21 To further solidify IMP-1’s role in development, IMP-1 
deficient mice were developed to determine potential phenotypic changes.22 The knockout mice 
exhibited dwarfism and the vast majority of the organs such as the brain, spleen, small intestine 
and liver exhibited hypoplasia. In terms of life-span, only 50% of mice lived 3 days postnatal. The 
rationale for organ hypoplasia was due to the alteration in mRNA transcript levels. In intestines, 
24 transcripts changed more than 2-fold; changes included alteration related to extracellular matrix 
transcripts, gene encoding carbonic anhydrase III and various others. The liver also experienced 
two fold changes in 20 different transcripts.22 The global RNA level changes were related to the 
function of IMP-1. 
Depending on when IMP-1 is expressed, it can either be beneficial or detrimental. Since 
IMP-1 is a RBP, it can bind to a wide array of mRNA transcripts during development and 
oncogenesis.  One of the main functions of IMP-1 is the protection from endoribonucleases.14 The 
role of IMP-1 shielding transcripts from endoribonucleolytic degradation was confirmed in 2006 
by Sparanese and Lee.23 IMP-1 protected the c-Myc and MDR-1 transcripts from degradation by 
the endoribonuclease, APE1 in a concentration dependent manner.23,24 Protection from micro RNA 
mediated degradation was also reported.25 IMP-1 prevented miR-183 from targeting βTrCP-1 for 
degradation by argonaute-2 (Ago2),  which is the catalytic subunit located in the RNA-induced 
silencing complex.25 Although, IMP-1 is necessary for embryogenesis, its ability to bind important 
oncogenes is detrimental during oncogenesis. IMP-1 is able to bind and protect βTrCP1, c-Myc, 
CD44, MDR-1 and KRAS.23,25–27 βTrCP1 is involved in the signaling pathway for ubiquitination 
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and proteasomal degradation of key substrates related to the inhibition of nuclear factor κB and β-
catenin.25 MDR-1 codes for the multi-drug resistance protein that allows for efflux of 
chemotherapeutic agents.28 c-Myc codes for the important transcription factor c-Myc which when 
expressed aids in the transcription of genes for growth and development pathways.29 CD44 codes 
for a cell-surface antigen which are involved in processes such as cellular adhesion, lymphocyte 
activation, angiogenesis and various other roles relating to the extracellular matrix.30 Important 
oncogene turnover rate is lowered through IMP-1 binding and thus will exacerbate the cancer 
condition.   
Prevalence of IMP-1 in varying cancers has been widely reported. The protein is found in 
58.5% of breast cancers, 81% of colorectal cancers and is found in basal cell carcinoma.31–33 The 
expression of IMP-1 also has a negative correlation with survival rates as found after examining 
patients with colorectal cancer; this indicates the protein is a good predictor of survival rate.34 Non-
small cell lung carcinomas (25%) and high grade brain cancers such as glioblasomas multiform 
(61%) also has expression of IMP-1.35 
1.5. Inhibitors of IMP-1 
Initial work on IMP-1 inhibitors focused on RNAi inhibition of IMP-1. In a study on 
osteosarcoma, miR-150 was found to be downregulated.36 Consequently, overexpression of miR-
150 in osteosarcoma cell lines was found to downregulate IMP-1 protein levels through transcript 
base-pairing at the 3321-3328 bp region of the 3’ UTR. Downregulation of IMP-1 led to decreased 
cell invasion and migration.36 MicroRNA miR-506 was found to target IMP-1 in glioblastoma 
cells and similarly suppressed cell proliferation and migration.37 Specific oligonucleotides were 
developed to inhibit the IMP-1-CD44 mRNA interaction and was found to reduced steady state 
levels of CD44 in vivo.26 Antibiotics such as neomycin and streptomycin were also tested in the 
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study. Although the antibiotics inhibited the binding interaction, the suggested rationale was due 
to non-specific nucleotide interactions.26 
 Currently there is only one reported small molecule inhibitor of IMP-1 that was deemed 
effective. Mahapatra, et al. (2013) analyzed 17600 small molecules using a high-throughput 
fluorescence anisotropy assay for inhibitors of the IMP-1-c-Myc mRNA interaction.38 Compounds 
were tested at a concentration of 5 μM and only molecules with more than 25% binding inhibition 
were sent for cellular analysis. IMP-1 was set at 10 nM while the c-Myc probe was set at 1 nM; 
this represented approximately 90% of maximal binding. Compounds which increased or 
decreased total fluorescence by 30% or greater were not included. The molecule labeled 6896009 
inhibited the interaction by 72% ± 3.6% and inhibited cell proliferation of IGROV-1 (ovarian 
cancer cell line) by approximately 50% as according to MTT assay. The structure of the molecule 
contains nitrogen heterocycles (Figure. 1.5.1).38 
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Figure 1.5.1. Structure of an IMP-1 inhibitor 6896009.38 
 
The vast majority of the other compounds either proved ineffective at inhibiting the 
interaction or were cytotoxic.38 The cytotoxicity was based on a counter-screen which employed 
IMP-1 negative PC-3 prostate cancer cells. The report of the novel inhibitor is monumental. 
Specific targeting of RBPs is a difficult task due to the lack of knowledge on the relationship 
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between sequence specificity for RNAs and integral structural motifs required for binding. 
Although, this molecule was able to inhibit the IMP-1-c-Myc mRNA interaction both in vitro and 
in vivo, little is known about the specific interaction between the protein and compound.38 
Currently there are no reports on the second generation variants of the lead molecule. Structural 
activity relationships would be necessary to progress forward in the development of IMP-1 
inhibitors. Knowledge on the molecule binding site with IMP-1 is also warranted.  
1.6. Oncogenic KRAS 
The Kirsten rat sarcoma viral oncogene (KRAS) is part of the RAS family of GTPase 
proteins that includes N-Ras and H-Ras.39 RAS proteins are 188 amino acids in length and shares 
similarity in the first 120 amino acids.40 KRAS, however, exists as two different splice variants 
named KRAS4A and KRAS4B.41 The KRAS4A splice variant is due to the additional exon 4A 
that is alternatively spliced in as compared to KRAS4B. Exon 4 is a highly variable region (HVR) 
for the RAS family and allows for differential post translational modification. In the case of 
KRAS4A, the HVR contains a site for palmitoylation at cysteine 180 whereas KRAS4B does not 
undergo this modification. A cluster of positively charged residues (PB2) on KRAS4A HVR from 
lysine 182 to lysine 185 allows for association with the plasma membrane through electrostatic 
interactions, even in the absence of palmitoylation. KRAS4B similarly relies on positively charged 
residues to interact with the inner plasma membrane. Tsai et al. removed the palmitoylation site 
and mutated the PB2 amino acids to neutral glutamine residues to determine localization changes 
of KRAS4A.41 Absence of both palmitoylation and PB2 for KRAS4A instead changed cellular 
localization exclusively to the endomembrane and cytosol. To add further complexity, KRAS4B 
interacts with the δ-subunit of cGMP phosphodiesterase type 6 (PDE6δ) for cytosolic transport to 
the plasma membrane whereas KRAS4A does not.41 
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A distinguishing factor of KRAS is the involvement in embryogenesis.42 KRAS knockout 
mice exhibited weakened ventricular walls and increased apoptosis of neural cells in the spinal 
cord.42 N-Ras knockout mice, however, did not exhibit deleterious effects during embryo 
development and were indistinguishable from wildtype mice post-natally.43 KRAS is suggested to 
be crucial for embryonic development.42,43 
The importance of KRAS is due to its position relative to its downstream effectors. Once 
localized on the plasma membrane, KRAS affects several major pathways (Figure. 1.6.1).44 In the 
inactive form, KRAS is normally bound to guanosine diphosphate (GDP). Association with a 
guanine exchange factor (GEF) such as Son of Sevenless 1 (SOS1) accelerates the exchange of 
GDP to GTP, thus activating KRAS for signal transduction. The two major pathways activated by 
KRAS are the canonical mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K); these pathways are intimately involved in cell cycle regulation.  
 
Figure 1.6.1. Downstream effectors of KRAS signaling.44 
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The MAPK pathway is responsible for cell cycle progression and transcription while PI3K is 
responsible for processes such as cell growth, survival and migration (Figure. 1.6.1). PI3K 
activation also leads to inhibition of the tumor suppressor p53.  Subsequent inactivation of KRAS 
occurs with GTP exchange that is enabled by GTPase-activating proteins (GAP) such as 
Neurofibromin 1 (NF1).44 
A single point mutation in KRAS results in deregulation of downstream effectors and is 
one of the main causes of KRAS driven cancers.7 Mutations commonly occur at glycine 12 (G12) 
for 85% of cases and can be mutated to aspartate, valine or cysteine. G12 mutations to arginine, 
serine or alanine exist but are much rarer.  Once mutated, steric hindrance at the active site occurs 
and prevents hydrolysis of GTP from RAS leading to a constitutive signaling state. Prevention of 
hydrolysis is due to the catalytic glutamine (Q61) shifting orientation in G12 substitutions.45 Q61 
normally coordinates with a water molecule to initiate hydrolysis of the γ-phosphate in GTP. 
Mutations at G13 (14% of cancers) and Q61 (2% of cancers) has also been reported.46 Since KRAS 
controls MAPK and PI3K pathways, the constitutive signaling leads to uncontrolled cell growth 
and progression resulting in a cancerous state.7 
KRAS driven cancers have been widely reported to this date. Malfunction in KRAS is 
found in 27.3% of lung adenocarcinoma, 98% of pancreatic ductal adenocarcinoma and 42.4% of 
colorectal cancer.47–49 The type of mutation also dictates phenotypic outcomes. In colorectal 
cancer, patients who harbor the valine (V) mutation at the glycine 12 position (G12V) had an 
increased rate of mortality by 30%.50 G12 mutations in murine NIH/3T3 fibroblasts resulted in 
lowered apoptosis, increased cell density and spontaneous anchorage independent growth; those 
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characteristics are hallmarks of cancer.51 The G13 mutation, however, did not have as pronounced 
phenotypic effects as the G12 mutation and had reduced cellular proliferation which in this case, 
is better for patient survivability.51 Proliferation of colorectal cancer cells was due to a KRAS 
G12D mutation and was mediated through activation of MEK in the MAPK pathway.52  
Not all KRAS driven cancers are due to mutation. Genetic analysis of primary endometrial 
carcinoma lesions revealed that 3% of total samples (414) contained KRAS gene amplification.53 
Patients who had amplification of KRAS was reported to have a lower 5 year survival rate of 46% 
compared to the 87% for cases which are unamplified. Compared to the primary cancer, metastatic 
lesion samples contained a higher percentage (18%) of gene amplification. The findings led to a 
new prognostic marker for metastatic endometrial carcinoma and inspired research into other 
targeted therapies.53 Due to the prevalence in cancers and the mutant-dependent phenotypic 
variance, KRAS has been a widely studied protein for potential targeted therapies.54 
1.7. Strategies for Targeting KRAS-Driven Cancers 
1.7.1. Inhibition by siRNA 
Like IMP-1, effective targeted therapies towards KRAS in the pre-clinical setting began 
with analysis of RNA interference. Two types of RNA were analyzed: small interfering RNA 
(siRNA) and micro RNA (miRNA). The difference between the two lies in origin; siRNA is 
synthetically produced, and miRNA is found endogenously.  An example of an effective miRNA 
is miR-143; overexpression of endogenous miR-143 in colorectal cancer cells reduced cell 
proliferation through targeting the 3’ UTR of the KRAS mRNA.55 In oral squamous cell 
carcinoma, miR-181a also targeted a region of the KRAS 3’UTR and reduced both cell 
proliferation and anchorage-dependent growth.56 Due to the success of the miRNA inhibition, 
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some researchers took the approach of siRNA therapies in the form of synthetic antisense 
oligonucleotides (AON). In 2017, Ross et al. designed a third generation AON called AZD4785 
(3ʹ-TTTCTGAGGATTATCG-5ʹ) that targets the 3’ UTR of KRAS and initiates RNAse H-
mediated degradation of the transcript.57 AZD4785 was designed with a phosphorothioate 
backbone and modified furanose rings containing constrained ethyl groups at the ends of the AON; 
3 nucleotides on each end were modified.58 Specifically, the 2ʹ OH of the furanose was modified 
to a 2ʹ,4ʹ-constrained 2ʹO-ethyl bridge causing a C3ʹ-endo pucker of the ring (Figure. 1.7.1). 
Conformationally locked nucleic acids (LNA) allows for improved hybridization with RNA as 
found previously with AON thermal melt (Tm) analysis. The Tm increased by 1.5°C with each LNA 
incorporation which indicated strengthened intermolecular association between the AON and the 
RNA. LNA design allowed for shorter sequences for AONs, from the traditional 22 nucleotides 
(nts) to 14 nts and protection from 3ʹ-exonucleases. However, LNA still suffered from poor 
pharmacodynamics in mouse models due to hepatotoxicity. Modification of the R group from H 
to (S)-cEt solved the hepatotoxicity issue while retaining similar EC50 to LNA (Figure. 1.7.1).58 
Due to the specificity, AZD4785 was able to down regulate KRAS without affecting N-Ras or H-
Ras in the A431 endometrial carcinoma cell line.57 Tumor size reduction was also seen upon 
treatment in the lung cancer patient derived xenograft (PDX) model, LXFA 983.57 No adverse 
events were found with AON treatment on murine and cynomolgus monkey models.57 Although 
the results were promising, the pharmacokinetics and pharmacodynamics of AZD4785 have yet to 
be tested in humans.  
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Figure 1.7.1. Chemical modification of the furanose rings in nucleosides for second 
generation antisense oligonucleotides.58 
 
As reviewed by Juliano et al. siRNA therapies encounter unfavorable barriers in terms of 
pharmacokinetics.59 The main barrier would be delivery to specific tissues. Although the 
phosphorothioate backbone enhances plasma stability, it causes non-specific interactions with 
proteins and in some cases, leads to heightened toxicity. The siRNAs have been found to 
preferentially bioaccumulate in the liver and kidneys. Increased dosing of siRNAs to compensate 
for accumulation merely led to an increase in renal excretion. A specialized macrophage in the 
liver, named Kupffer cells, also uptake foreign siRNA through phagocytosis and shuttles the 
phagosome to the lysosome for enzymatic degradation. Of the siRNA that reach the target tissue, 
it is still subject to the rate-limiting steps of crossing the plasma membrane and subsequent release 
from endosomes into either the cytoplasm or the nucleus.59 Due to the challenges of siRNA 
treatments, KRAS researchers also focused on other druggable aspects in regards to post-
translational modification, sub-cellular trafficking, protein activation and related effector 
pathways. 
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1.7.2. Post-translational Inhibition by FTI and GGTI 
Inhibition of KRAS post-translational modification was one of the approaches attempted. 
Farnesyl transferase inhibitors (FTI) were once considered a method for inhibiting the RAS family 
of proteins (Figure. 1.7.2.).60,61 FTIs function by inhibiting the farnesyl transferase protein that 
targets RAS for prenylation at the CAAX motif. Once inhibited, the RAS protein is unable to 
anchor to the plasma membrane and remains inactive.  
  
FTI GGTI 
Figure 1.7.2. Inhibitors of KRAS prenylation.61 
 
Unfortunately, most of the studies focused on inhibiting the related H-Ras protein family 
member. Through further studies, researchers found that the KRAS4B variant and N-Ras were 
able to be post-translationally modified by the geranylgeranyl transferase 1 enzyme. With the 
addition of the geranylgeranyl group, both KRAS4B and N-Ras variants were able to anchor 
normally to the plasma membrane thus rendering FTIs ineffective.60 Combination therapy with 
FTI and geranylgeranyl transferase inhibitors (GGTI) were attempted in order to specifically target 
KRAS.61 Although the treatment proved effective in vivo, the dosage required for KRAS inhibition 
in a mouse model was severely toxic.61  
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1.7.3. Inhibiting Sub-cellular Trafficking by Targeting PDE6δ  
 Failure in targeting prenylation led to a focus on the inhibition of the interaction between 
PDE6δ and KRAS. The success of disruption would lead to sub-cellular localization of KRAS to 
the endomembrane leading to inactivation. In 2018, Chen et al. used a fragment-based drug design 
(FBDD) to create improved inhibitors of PDE6δ.62 Prior attempts at inhibition resulted in the 
design of the benzimidazole inhibitor named Deltarasin (Figure. 1.7.3A).  
A) C) 
 
 
B) 
 
Figure 1.7.3. Inhibitors of the PDE6δ-KRAS interaction. (A) Deltarasin, (B) 
quinazolinone-imidazole inhibitor 11b, (C) Molecular docking of 11b to PDE6δ.62 
 
Although the drug had nanomolar affinity for PDE6δ, other non-specific interactions 
resulted in cytotoxicity. The FBDD approach revealed two active sites within PDE6δ. High affinity 
fragments were linked together as the basis of the newer lead compound. Structural activity 
relationship analysis led to the discovery of the quinazolinone-imidazole inhibitor, 11b (Figure. 
19 
 
1.7.3B). Through molecular docking, the new compound was found to hydrogen bond with 
arginine 61 and glutamine 88 (Figure. 1.7.3C). Treatment with 11b in Capan-1 pancreatic 
adenocarcinoma cells led to downregulation of the KRAS downstream effectors, Erk and Akt. 
Further proof of KRAS inactivation was seen in the enhanced sub-cellular localization of the 
protein to the endomembrane and concomitant apoptosis at 25 μM concentration.62 The PDE6δ 
inhibitor presents an alternative method for targeting KRAS driven cancers, however, more 
optimization work would be required to lower the dosage before attempting murine models. 
Targeting GEFs which activate KRAS for signaling is the next logical step if disruption of sub-
cellular localization is deemed ineffective. 
1.7.4. KRAS Activation Lowering by SOS1 Inhibition  
 As mentioned previously, SOS1 predominantly catalyzes the exchange of GDP to GTP for 
KRAS activation. Thus, small molecule intervention to prevent SOS1 association with KRAS was 
explored. Using FBDD, Maurer et al. screened for novel compounds which interact with KRAS.63 
Through heteronuclear single quantum coherence spectroscopy (HSQC) analysis of GDP-bound 
KRAS, a compound called  DCAI was found to shift the residues V8, L56, D57 T74, and G75, 
suggesting a physical association with KRAS (Figure. 1.7.4). 
 
Figure 1.7.4. DCAI: An inhibitor of the SOS1-KRAS interaction.63 
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The residue site was found to be adjacent to the SOS1-KRAS interaction surface. DCAI 
was found to block SOS1-mediated nucleotide exchange in an in vitro nucleotide release assay. 
KRAS inactivation was detected in DCAI-treated HEK293T kidney cells as indicated by reduction 
of cRAF recruitment to the plasma membrane.63 Unfortunately, there were no further tests in 
cancer cell lines. DCAI merely represented the first step in designing a mature drug for the 
inhibition of SOS1 activation of KRAS. As part of FBDD, additional fragments which can bind 
adjacent surfaces of KRAS would need to be discovered. Through linking high affinity fragments, 
a more mature drug can be designed.   
1.7.5. Mutant-specific Inhibition of KRAS G12C 
Direct targeting of KRAS is notoriously difficult due to the protein’s picomolar affinity 
towards GTP/GDP.64 Despite the difficulties, a novel allosteric site within the KRAS G12C mutant 
was reported in a landmark journal article.65 Ostrem et al. screened fragments for their ability to 
target the nucleophilic thiol of the cysteine 12 (C12) residue. C12 was chosen due to its location 
in the nucleotide binding pocket between switch I and switch II (Figure. 1.7.5C). Switch I and 
switch II were known for their conformational shift upon GTP/GDP binding. The fragment screen 
resulted with compound 6H05 being the most suitable hit (Figure. 1.7.5A). Co-crystallization of 
6H05 with KRAS revealed the new allosteric site that was not previously found with other crystal 
structures (Figure. 1.7.5C). The residues glycine 60 and glutamate 99 form hydrogen bonds with 
6H05 causing reordering of switch II residues and creating the switch II pocket (S-IIP). Further 
structure-activity relationship analysis of 6H05 revealed the new structure 12 that utilizes 
acrylamide as the electrophile (Figure. 1.7.5B). The rationale for the structural shift was to create 
a molecule that bound irreversibly to the mutant form which was a characteristic that was not seen 
with the disulphide compounds. Binding of the molecule causes KRAS G12C mutant to 
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preferentially bind GDP leading to the inactive state. In addition, the molecule impairs Raf 
association with KRAS which further downregulates the MAPK pathway.65 Further modifications 
of the G12C inhibitor by Ostrem et al. was performed by a joint project between Array BioPharma 
and Mirati Therapeutics in 2018.66 The authors kept the fragment containing the acrylamide linker 
and piperazine ring but made modifications to optimize non-covalent interactions in the S-IIP 
(Figure. 1.7.5D). 
A) C) 
 
 
B) D) 
 
 
Figure 1.7.5. Allosteric inhibitors of KRAS G12C. A) Molecule 6H05, B) Molecule 12, C) 
Co-crystal of KRAS with 6H05 (cyan) and GDP, D) Array BioPharma & Mirati Therapeutics 
modification.65,66  
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Addition of the naphthalene ring allowed the compound to occupy a hydrophobic space 
proximate to methionine 72 in the S-IIP. The naphthalic hydroxyl group also allowed hydrogen 
bonding to aspartate 69, thus creating more specificity.66 The ability to target the G12C mutant is 
a monumental breakthrough and will pave the way for clinical trials for a sub-sector of the 
population. However, there are currently no other specific compounds for the other allelic forms 
of KRAS since the acrylamide linker only allows targeting of the cysteine residue.  
1.7.6. Targeting Effectors in Related Pathways 
Current efforts for treating KRAS driven cancers relies on the vulnerabilities of targets in 
related effector pathways but the approach suffers from some disadvantages. The epidermal 
growth factor receptor (EGFR) is part of the signaling cascade leading to SOS activation of 
KRAS.67  EGFR inhibition have been studied in the past and led to the development of FDA 
approved drugs such as Erlotinib.68 Although patients respond well initially to the treatment, there 
is an inevitable acquired resistance from a secondary mutation. The mechanism for resistance lies 
in the mutation at exon 20 of the EGFR gene causing an amino acid substitution of threonine to 
methionine at position 790 (T790M).68  
Inhibition of downstream effectors of KRAS have also been a popular approach. Raf-1 
(alternate name of c-RAF) in the MAPK pathway is commonly inhibited by the potent drug, 
Sorafenib.69  The success of the drug lies in its ability to also inhibit important targets such as 
vascular-endothelial growth factor receptor (VEGFR) and the Raf homologue, BRAF.69 
Resistance to Sorafenib have been reported.70 Cells which are resistant have been found to be more 
invasive and less reliant on anchorage-dependent growth.70 Mek inhibition with the allosteric 
inhibitors such as Trametinib, is another potential approach.71 The disadvantage of inhibiting Mek 
is the low therapeutic index. As reported in a phase II study, treatment with Trametinib at 
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meaningful therapeutic dosages can cause serious retinopathy in some patients; however, the 
findings are an improvement over predecessor drugs.71 
The RAS field has grown substantially over the past few decades since its discovery as an 
oncogene and great effort at producing drugs for RAS-driven cancers have been documented. 
However, the direct targeting of all mutant forms of KRAS remains a monumental challenge. The 
investment into alternative approaches remains important. A field of the research is focused on the 
post-transcriptional regulation of KRAS. If one can down-regulate translation of KRAS in the 
implicated cancers, then the hypothesized result would be a subsequent decrease in proliferation.    
1.8. Interaction Between KRAS and IMP-1 
In 2011, Mongroo et al. confirmed the interaction between IMP-1 and KRAS from analysis 
of human colorectal cancer cells.27 In an effort to characterize the IMP-1-c-Myc interaction, siRNA 
against IMP-1 was transfected into SW480 colorectal cells. Western blot analysis showed that loss 
of IMP-1 did not change protein levels of c-Myc but lowered KRAS protein levels by 60%. Cell 
proliferation, growth and survival were also reduced with the siRNA treatment. Since IMP-1 
regulates many oncogenes, a UV cross-linking experiment was performed to determine possible 
association with the KRAS transcript. After cross-linking, IMP-1 was immune-precipitated and 
was found to be in complex with both the coding region and 3’ UTR of KRAS.27 
In 2018, Mackedenski et al. performed a more specific analysis of IMP-1 interaction with 
the KRAS transcript.72 Specificity for KRAS was further refined to the 1-185 nts segment of the 
coding region after systematic analysis of transcript fragments using the electrophoretic mobility 
shift assay technique. GXXG mutational experiments were also performed to determine domain 
requirements for binding the 1-185 nts fragment. It was found that all four KH domains are 
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required for high affinity towards the substrate. Immunoprecipitation experiments involving 
expressed mutant proteins in HeLa (ovarian cancer) cells verified the result (unpublished).20  
A fluorescence polarization method was developed in an effort to conveniently study 
IMP1-RNA interaction and to screen for inhibitors of the IMP-1-KRAS mRNA interaction.73 Ms. 
Chuyi Wang, a prior lab member, screened a small library of 217 molecules of which a subset 
were dispiropyrrolizidine derivatives. Fluoresence anisotropy assay analyses revealed a positive 
hit called UNBC152, which inhibited the IMP-1-KRAS mRNA interaction in vitro (Figure. 1.8.1). 
 
Figure 1.8.1. UNBC152 inhibitor of the IMP-1-KRAS mRNA interaction.73 
 
Subsequent testing of UNBC152 in two colorectal cancer cell lines confirmed knockdown 
of KRAS protein levels.73 The current model for the interaction of the drug is illustrated in Figure 
1.8.2. In the presence of the inhibitor (UNBC152), IMP-1 is prevented from interacting with the 
KRAS transcript. KRAS RNA is then readily exposed and is vulnerable to decay by miRNA or 
endoribonuclease. 
25 
 
 
Figure 1.8.2. Hypothesis for the UNBC 152 inhibition of IMP-1-KRAS interaction. 
Interaction with either miRNA or siRNA will lead to translational inhibition and a 
subsequent decrease in KRAS protein levels. With the down-regulation of protein, proliferation of 
cells would decrease. The alternative pathway leading to endoribonucleic degradation of the KRAS 
after IMP-1 inhibition have yet to be seen. 
1.9 Principle of Fluorescence Polarization 
As reviewed by Lea, fluorescence polarization (FP) analyzes molecular interactions 
through the usage of linearly polarized light.74 The linear light causes excitation in a fluorophore 
and emission is read by either a parallel or perpendicular emission polarizer.74 For the analysis of 
the IMP-1-KRAS mRNA interaction, the activity was monitored indirectly by excitation of the 
fluorescein-labeled KRAS substrate (KRAS-FL). The degree of polarization of KRAS-FL was 
dependent on both Brownian motion and ability to bind to IMP-1.74 The principle of FP is based 
on Perrin’s 1926 equation as follows: 𝜇𝜇 = (3𝜂𝜂𝜂𝜂)/(𝑅𝑅𝑅𝑅). The molecular relaxation time (µ) is 
proportional to the viscosity of the environment (𝜂𝜂), and the molecular volume (V). Molecular 
relaxation is inversely proportional to the gas constant (R) and temperature (T). Assuming stable 
atmospheric pressure, temperature and consistent viscosity, the rotation of the fluorophore is 
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dependent solely on the molecular volume.74 As the control, unbound KRAS-FL was tested in 
absence of IMP-1 protein. Since the molecular volume of the probe was low, the fluorophore 
tumbled rapidly in solution leading to scattering of the plane-polarized light (Figure. 1.9.1A.).  
A 
 
B 
 
Figure 1.9.1. Principle of fluorescence polarization assay. (A) Scattering of polarized light 
by unbound fluorophore, (B) Maintenance of polarized light by bound fluorophore. Image 
adapted from www.hi-techsci.com.  
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Upon reception by polarized filters, there was only a marginal difference between 
perpendicular and parallel light which lead to low FP units.  When KRAS-FL bound to IMP-1, the 
molecular volume vastly increased thus the tumbling of the complex slowed down. The slower 
tumbling of the complex resulted in a significant increase of fluorescence polarization when 
compared to the random motion of unbound KRAS-FL (Figure. 1.9.1B.).   
2.0 Research Goals 
 This project is a continuation of the research on the UNBC152 compound, a molecule that 
has shown potential to inhibit the interaction between IMP-1 and the mRNA substrate, KRAS. 
Specifically, this project was focused on the confirmation of the active component of UNBC152, 
which, after chemical analysis, was discovered to be a complex mixture of components. 
Due to the nature of high-throughput library creation by parallel synthesis, individual 
compounds within a screening library, including UNBC152, are not necessarily confirmed to be 
pure. Therefore, a further refinement of the bioactive mixture is often necessary for substrate 
characterization and potential enhancement of bioactivity. To further add to this complexity in this 
particular case, the collaborator, Dr. Yeong Keng Yoon from Universiti Sains Malaysia, 
synthesized three batches of the UNBC152 compound, yet all 3 batches exhibited marked 
differences on ability to disrupt the IMP-1-KRAS RNA interaction as assessed by fluorescence 
polarization method. 
 The first goal of my project was to synthesize UNBC152 in-house using the collaborator’s 
protocol and compare the composition of the synthesized batch to the original batch showing high 
activity towards the inhibition of the interaction between IMP-1 and KRAS mRNA. The second 
goal was to devise a purification strategy for the consistent isolation of any molecules of interest 
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within the UNBC152 mixture and the structural elucidation of these molecules. The third goal was 
to validate the performance of the purified products against the original high-activity batch of 
UNBC152, and to determine which pure species contributed to the original cellular activity in 
colorectal cancer cell (CRC) lines. 
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Chapter 2 
 
Synthesis, Purification and Characterization of Spiropyrrolizidine 
and Piperazine Derivatives 
  
The main goal of this study was to find an inhibitor of the IMP-1-KRAS mRNA interaction. 
It began with a library screen conducted by Ms. Chuyi Wang of 217 small molecules generated by 
our collaborator, Dr. Yeong Keng Yoon from Universiti Sains Malaysia. The library was screened 
using the fluorescence polarization (FP) method (Section 1.9). Of the 217 samples screened, two 
spiropyrrolizidine derivatives were found to lower the percent bound of IMP-1 to KRAS mRNA: 
UNBC152 and UNBC143. UNBC152 was the most effective in lowering the fluorescence 
polarization signal; thus, suggesting that the percentage bound of IMP-1 to the fluorescein-labeled 
KRAS probe (KRAS-FL) was also lowered. LC-MS analysis by Dr. Yeong’s group, however, 
revealed that UNBC152 contained a complex mixture of compounds, most of which were 
unrelated to the proposed product (Figure 1.8.1). To add further complexity, the collaborator also 
synthesized three batches of UNBC152, and each batch had varying activity in the FP assay. The 
third batch of UNBC152 (UNBC152-3) was the most potent.  
This chapter examines the synthesis and evaluation of the molecules present in UNBC152 
and the comparison of various synthetic batches with UNBC152-3 by thin layer chromatography 
(TLC), high performance liquid chromatography (HPLC) and low-resolution electrospray 
ionization mass spectrophotometry (LRESI-MS). The rationale for switching focus to the synthesis 
and purification of a dispiropiperazine derivative (SPOPP) will be discussed as well. Purification 
of the compounds was performed using flash chromatography as the initial step and HPLC was 
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used to refine the semi-purified product in order to meet biological assay requirements (≥95 % 
purity).  Furthermore, purification of several side products formed during the synthesis of SPOPP 
was conducted to determine if there were other molecules with potential bioactivity. The 
experiments of this chapter were guided by results from biological analyses such as FP assay, 
Western blot, and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Specific details regarding the bioassays conducted will be discussed in Chapter 3. Structural 
characterization using NMR was performed for validation of the correct product.  
2.1 Methodology – Synthesis, Purification and Characterization of Spiropyrrolizidine and 
Piperazine Derivatives 
 
2.1.1. General information 
 Synthesis materials (acenaphthenequinone, 1-indanone, 2-bromobenzaldehyde and 
proline) were purchased from Sigma Aldrich and used without further purification. Solvents such 
as methanol, acetonitrile, hexanes and ethyl acetate were HPLC grade quality, purchased from 
either Sigma Aldrich or Fischer Scientific and used without further purification.  Thin layer 
chromatography was performed on aluminum plates pre-coated with 0.2 or 1 mm silica gel with 
fluorescent indicator (UV254) or 0.2 mm reverse phase (C18, 23% carbon load). Flash 
chromatography columns were packed with 230-400 mesh silica gel (Silicycle) or reversed phase 
C18 (23% carbon load, 230-400 mesh; Silicycle).  HPLC was performed using an Agilent 1200 
Infinity series; the fraction collector module was the Agilent 1260 Infinity II series. Low resolution 
mass spectrophotometry (electrospray ionization) was performed using an Agilent 6120 LC-MS 
module. NMR structural characterization utilized either a Bruker Fourier 300 or Bruker Avance 
600 system. 
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2.1.2. Synthesis of (2E)-2-(2-bromobenzylidine)-1-indanone (3)75 
 
 
O O
O
BrBr
+ NaOH
EtOH, rt
1 2 3
H
 
Figure 2.1.1. Reaction scheme for the synthesis of (2E)-2-(2-bromobenzylidine)-1-
indanone (3). 
 
 An equimolar ratio of 1-indanone (1, 19.5 mmol) and 2-bromobenzaldehyde (2, 19.5 
mmol) was dissolved in 195 mL of ethanol (Figure. 2.1.1). To the mixture, 100 mL of 1M NaOH 
(aq) was added slowly while stirring, producing a white precipitate. The reaction stirred at room 
temperature for 4 h and reaction progress was monitored by TLC (1 ethyl acetate: 2 hexanes). 
Upon completion of the reaction, the solution was neutralized to pH 7 using 6 M HCl. The 
precipitate was removed by vacuum filtration and washed sufficiently with H2O. After air drying, 
the precipitate was recrystallized with 100% methanol to yield the (2E)-2-(2-bromobenzylidine)-
1-indanone product (3, 3.701g, 63%).  
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2.1.3. Synthesis of UNBC152 (7)76 
 
Figure 2.1.2. Synthesis of spiropyrrolizidine derivative, UNBC152 (7). 
 
 An equimolar mixture of 3 (299 mg, 1 mmol), 4 (182 mg, 1 mmol) and 5 (115 mg, 1 mmol) 
was added to 10 mL of methanol (Figure. 2.1.2). The mixture was heated to reflux for 6 h and 
progress was monitored by TLC (1 ethyl acetate: 2 hexanes). After cooling, the product was 
isolated by vacuum filtration to yield the crude product as a yellow-colored solid (384 mg).  
 
2.1.4. Synthesis of spiro[2′,3]-bis(acenaphthene-1′-one)perhydrodipyrrolo- [1,2-a:1,2-d]-
pyrazine (SPOPP; 8) and NP6A77 
 
 
Figure 2.1.3. Synthesis of dispiropiperazine derivatives SPOPP (8) and 9. 
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An equimolar mixture of 4 (1.822 g, 10.0 mmol) and 5 (1.151 g, 10.0 mmol) was heated in 
10 mL of 100 % methanol. Reaction temperature was set at either 25, 35, 45 or 55 °C and reaction 
time was set between 1.5 and 24 h (Table 2.1.1.). Reaction progress was monitored using TLC (1 
ethyl acetate: 2 hexanes). Typically, an orange precipitate was formed during the first hour. This 
precipitate changed to an orange-brown color after ~1 h reflux time and to a dark brown color after 
completion of the reaction. 
Table 2.1.1. Crude batches of 8 synthesized at varying times and temperatures.  
Name Time (h) Temperature (°C) 
VLA21 3 64 
VLA25 3 64 
VLA37 3 35 
VLA159 3 35 
VLA161 24 25 
VLA175 3 45 
VLB133 3 55 
VLB135 3 35 
VLB187 1.5 35 
 
The solvent was removed under reduced pressure leaving a dark brown powder (1.772 g). 
Crude product containing both 8 and NP6A (250 mg) was mixed with 2 g of normal phase silica 
in 200 mL of 100 % methanol. Solvent was removed under reduced pressure and the silica mixture 
was dry-loaded into the column (10.5 cm height x 3.1 cm diameter). Purification by flash 
chromatography, using normal-phase silica (50 g) and a 9:1 mixture of hexanes and ethyl acetate 
at a flow rate of 12 mL/min resulted in the isolation of SPOPP (8) and NP6A. Two fractions, a 
yellow-colored band eluting at 320-405 mL and an orange-colored band eluting at 530-830 mL, 
were isolated. The purification of crude material was conducted 3 times and 686 mg of crude 
material was processed.  The semi-purified orange product was dried under reduced pressure to 
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produce 280 mg of semi-purified SPOPP (8). SPOPP (8) was subsequently purified by HPLC 
using a Phenomenex phenyl-hexyl column (4.6 x 250 mm, 5 micron) and the purification 
procedure listed in Table 2.1.2. For the orange product (retention time of 4.08 min), a total of 12.5 
mg was injected into the HPLC and 5 mg (40 %) of purified SPOPP (8) was retrieved.  
Table 2.1.2. HPLC purification procedure for SPOPP (8) and NP6A. 
Time 
(min) 
H2O 
(%) 
Acetonitrile 
(%) 
Flow rate  
(mL/min) 
0 20 80 2 
6 8 92 2 
8 20 80 2 
 
NP6A, which was eluted as the yellow-colored band between 320-405 mL from the same 
purification step as SPOPP (8), produced 120 mg of semi-purified, yellow-colored NP6A after 
solvent was removed under reduced pressure. NP6A was also HPLC purified using the phenyl-
hexyl column and the purification scheme listed above in Table 2.1.2. For the yellow product 
(retention time of 6.02 min), a total of 120 mg was injected into the HPLC and 21 mg (17.5 %) of 
purified NP6A was retrieved. 
2.2 Results and Discussion 
2.2.1. Synthesis of (2E)-2-(2-bromobenzylidine)-1-indanone (3) 
 The synthesis of UNBC152 (7) began with the preparation of the starting reagent (2E)-2-
(bromobenzylidene)-1-indanone (3). The reaction proceeds via a base-catalyzed aldol 
condensation of 1-indanone (1) with 2-bromobenzaldehyde (2, Figure. 2.2.1.1). Deprotonation of 
1-indanone (1), followed by nucleophilic attack on the carbonyl carbon of 2-bromobenzaldehyde 
(2) and proton transfer, led to the formation of the aldol product. Subsequently, dehydration 
yielded the condensation product 3. 
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Figure 2.2.1.1. Mechanism for the base-catalyzed aldol condensation between 1-indanone 
(1) and 2-bromobenzaldehyde (2). 
 
 The reaction was monitored using TLC. As seen in Figure 2.2.1.2, the 1-indanone (1) can 
be monitored using the vanillin stain whereas the 2-bromobenzaldehyde (2) was better monitored 
using UV light (short wave). When stained and heated, the 1-indanone (1) changes to a deep red 
color. 
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Figure 2.2.1.2. TLC reaction monitoring for the synthesis of (2E)-2-(Bromobenzylidene)-
1-indanone (3). Normal phase TLC used (1 ethyl acetate: 2 hexanes); Visualized with vanillin 
staining.  
 
Tracking the depletion of 1-indanone (1) as a marker for reaction completion was then 
relatively easy. Upon the addition of the 1M NaOH, the reaction began immediately. Reaction 
progress was monitored from 0 h and presence of 1-indanone (1, Rf = 0.53) was seen in reaction 
lane C. After 2 h, the reaction was monitored again and a new spot (Rf = 0.6) appeared which had 
a migration distance between 2-bromobenzaldehyde (2, Rf = 0.73) and 1-indanone (1). The 
reaction lane C did not contain presence of 1-indanone (1) as indicated by the lack of a red spot at 
Rf = 0.6. The reaction proceeded for another hour before the product was filtered. In order to ensure 
purity of the compound and to save time, the white precipitate was recrystallized in 100% 
methanol. After recrystallization, thin ivory-colored crystals remained. From the initial 2.575 g of 
1-indanone (1) and 3.60 g of 2-bromobenzaldehyde (2) used for the reaction, 3.701g (63%) was 
retrieved in crystalline form.  
2.2.2. Synthesis of UNBC152 (7)76 
 The formation of UNBC152 (7) was the result of a 1,3-dipolar cycloaddition reaction 
between an azomethine ylide (6) and (2E)-2-(2-bromobenzylidine)-1-indanone (3), which is a 
37 
 
popular synthetic route towards the regio- and stereoselective formation of 5-membered ring 
heterocycles.77 The synthesis began with a reaction between ʟ-proline (5), acenaphthenequinone 
(4, Figure. 2.2.2.1.). Acenaphthenequinone (4), in presence of weak acid, is protonated and 
subsequently undergoes nucleophilic attack by the nitrogen from the ʟ-proline (5). Proton transfer 
and dehydration generated zwitterionic iminium ion (I) which cyclizes to the lactone intermediate 
(II). Subsequent decarboxylation provides the azomethine ylide for the next part of the reaction.  
 
Figure 2.2.2.1. Formation of the azomethine ylide (6) from the reaction between 
acenaphthenequinone (4) and ʟ-proline (5). 
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The formation of the azomethine ylide is key to the success of the 1,3-dipolar cycloaddition. Once 
generated, it reacts with (2E)-2-(2-bromobenzylidene)-1-indanone (3), as shown in Figure. 
2.2.2.2., to form UNBC152 (7) in a concerted fashion. 
 
Figure 2.2.2.2. Mechanism for the 1,3-dipolar cycloaddition formation of UNBC152 (7). 
 
 The reaction began with the reflux of equimolar portion of 3, 4, and 5. Reaction progress 
was monitored by normal phase TLC with the solvent system of 1 ethyl acetate: 2 hexanes (Figure. 
2.2.2.3). At 0 h, differences in spots on the TLC can be seen in the reaction lane D. There is a long 
streak below reactant 3 (Rf = 0.63) that persisted past reactant 4 (Rf = 0.45). Disappearance of 
reactant 4 was seen at the 2 h and 20-min mark. The reaction was carried out for another 20 min 
past the 6 h reaction time as previously recommended by Dr. Yeong Keng Yoon. 
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Figure 2.2.2.3. Reaction monitoring for the synthesis of UNBC152 (7). Normal phase TLC 
used (1 ethyl acetate: 2 hexanes); Visualized with short wave UV. 
 
The rationale for extending the time was to ensure most of the reactants have been consumed in 
the reaction. However, even beyond the 6 h mark, some of reactant 3 remained as indicated by the 
reddish-colored spot at Rf = 0.63. Since the lab was interested in investigating the rationale for the 
third batch of UNBC152’s (UNBC152-3, 7) biological activity, the sample was compared to the 
newly synthesized batch (VLA9, 7) by TLC as an initial low-resolution analysis (Figure. 2.2.2.4.).  
 
Figure 2.2.2.4. Comparison of various batches of UNBC152 (7). Normal phase TLC used (1 
ethyl acetate: 2 hexanes); Visualized by short wave UV.  
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UNBC152-3 (7) did contain some of reactant 3 but three other spots at Rf of 0.55, 0.29 and 0.0 
were also present. VLA9 (7) shared similar spots as compared to the 1st batch of UNBC152 (7, 
UNBC152-1). When both samples were compared to UNBC152-3 (7), however, both lacked the 
streak found below Rf of 0.27. Since UNBC152-3 (7) had the most biological activity based on the 
highest reduction of fluorescence anisotropy (FA) units in FA analysis of the IMP-1-KRAS 
mRNA interaction, it was hypothesized that the contents within the streak were responsible for 
the in vitro activity. To test this hypothesis, crude VLA9 (7) was sent forth for initial 
biological testing. It should be noted that although crude material was not optimal for biological 
testing, the original batches of UNBC152 (7) were also tested as a crude material; this idea offered 
at least a first basis for comparison. 
2.2.3. Synthesis of Spiro[2′,3]-bis(acenaphthene-1′-one)perhydrodipyrrolo- [1,2-a:1,2-d]-
pyrazine (8) 
 
 As reported by Haddad et al. in 2015, the 1,3-dipolar cycloaddition which utilized ʟ-
proline and acenaphthenequinone as the azomethine ylide can have a side reaction.77 The ylides 
(6) dimerize together to form the fused dispiropiperazines 8 and 9 (Figure. 2.2.3.1). As proposed 
by Haddad, the ylide forms in the transoid or cisoid orientation leading to the two dominant 
products of 8 and 9 with the other isomers 8ʹ and 9ʹ not formed due to steric hinderance. 
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Figure 2.2.3.1. Proposed Mechanism of SPOPP (8) by S. Haddad et al. 2015.77 
 
Since this side reaction can occur, we wanted to synthesize 8 and 9 as controls for our 
bioassay. Equimolar parts of ʟ-proline (5) and acenaphthenequinone (4) were dissolved in 100% 
methanol and the reaction was monitored by TLC over ~3-h (Figure. 2.2.3.2). A TLC sample 
taken at the start of the reaction (0 h) displayed three additional spots to the starting material at 
the Rf of 0.0, 0.57 and 0.64.  
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Figure 2.2.3.2. Reaction monitoring for the synthesis of Spiro[2′,3]-bis(acenaphthene-1′-
one)perhydrodipyrrolo- [1,2-a:1,2-d]-pyrazine (8). Normal phase TLC used (1 ethyl acetate: 
2 hexanes); Visualized with short wave UV. 
 
At the beginning of this investigation, it was quickly determined that the UNBC152-3 (7) 
reaction was complex and can produce multiple compounds that could be responsible for the 
previously observed bioactivity. Initially, the reaction produced an orange-colored precipitate. 
Beyond the 1 h mark, the precipitate began changing to a brown color. The presence of additional 
TLC spots from 0.0 to 0.25 Rf were first seen in reaction lane C after ~1 h, which suggested the 
creation of newer compounds not observed with VLA9 (7). After ~3 h, the TLC results did not 
appear to change and thus the reaction was stopped. By naked-eye, a yellow spot (Rf = 0.1) and 
an orange spot (Rf = 0) were observed, which was consistent with UNBC152-3 (1 ethyl acetate: 2 
hexanes; Figure. 2.2.3.2.). Haddad reported that compounds 8 and 9 were orange and yellow 
respectively, which suggested that this reaction had generated these molecules as well. The crude 
material (VLA25, 8/9) was dried under reduced pressure and then compared to UNBC152-3 (7) 
by TLC (Figure. 2.2.3.3.). 
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Figure 2.2.3.3. Comparison between UNBC152 (7) and the two-component synthesis 
VLA25 (8/9). Normal phase TLC used (1 ethyl acetate: 2 hexanes); Visualized with short wave 
UV. 
 
From analysis, the UNBC152-3 (7) and VLA25 (8/9) both contained the tailing at the early 
retention factor region from 0.0 to 0.27. Since UNBC152-3 (7) was the most bioactive and VLA25 
(8/9) also contained early Rf compounds, it was hypothesized that the piperazines 8 and 9 were 
responsible for the biological activity. More information on the bioassays will be given in chapter 
3. In brief, FP analysis of VLA9 (7) on the IMP-1-KRAS determined that the mixture was not able 
to abrogate the interaction. The result was shocking considering the UNBC152-3 (7) was able to 
lower FP units in a dose-dependent manner. However, the VLA25 (8/9) sample was able to lower 
FP units, suggesting the inhibition of the IMP-1-KRAS mRNA interaction. Additionally, the 
VLA25 (8/9) sample was able to inhibit the interaction better than the original UNBC152-3 (7) 
sample created by our collaborator. The project focus was then switched from the purification of 
the 3-component synthesis of the 1,3-dipolar cycloaddition (isolation of 7 from UNBC-152) to the 
isolation and purification of 8 and 9. The purified compounds would then act as controls for the 
biological testing and would be compared against UNBC152-3 (7). 
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2.2.4. HPLC-MS Analysis of Synthesized Products. 
2.2.4.1. Comparison of UNBC152 (7) and VLA9 (7) 
 In order to confirm the assumptions resulted from the HPLC and LRESI-MS analyses of 
the crude reaction mixtures described above, the development of an isolation procedure for the 
compounds of interest was undertaken. In order to obtain higher resolution information on the 
components of UNBC152-3 (7) and VLA9 (7), the crude products were separated by means of 
high-performance liquid chromatography (HPLC). Material was purified using the Phenomenex 
phenyl-hexyl 4.6 x 250 mm analytical column using a gradient solvent system (80:20 acetonitrile 
to H2O initial; increase to 100% acetonitrile in 10 min). C18 was the initial matrix used, however, 
it was found that the phenyl-hexyl modification provided not only the hydrophobicity required for 
separation of spiropyrrolizidine compounds, but it also reduced the peak tailing (data not shown). 
Additionally, the phenyl group is theorized to have potential for greater π-π interaction with the 
naphthalene rings of 7 and provides alternate selectivity for stereoisomers. The gradient system 
also reduced peak width (data not shown). During the separation of UNBC152 (7) by HPLC, three 
dominant peaks were observed using a variable wavelength detector (VWD) set at 265 nm (Figure. 
2.2.4.1). The peaks were found at 5.627, 6.945 and 7.996 min. VLA9 (7) also contained multiple 
peaks (5.335, 6.606, 7.640, and 9.108 min) using the same experimental conditions, however, the 
two reaction mixtures did not share many similarities in retention time. 
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Figure 2.2.4.1. HPLC VWD analysis and comparison of UNBC152-3 (7) and VLA9 (7). 
Absorbance was monitored at using a VWD at 265 nm. Analytes were chromatographed using 
a phenyl-hexyl 4.6 x 250 mm column with a gradient solvent system (80:20 acetonitrile: H2O to 
100% acetonitrile in 10 min; flow rate of 1 mL/min). 
 
Electrospray ionization mass spectrophotometry was utilized to determine the low-
resolution mass of the peaks identified by the HPLC separation (Figure. 2.2.4.2.). After separation 
by HPLC, a portion of the analytes were diverted to the mass spectrophotometer solvent stream 
which contained 0.1% formic acid. In brief, the formic acid acts as a positively charged vehicle to 
shuttle the analytes.78 Analytes exit the capillary tube inside the MS chamber and forms a Taylor 
cone. Eventually the coulombic repulsion forces exceed the surface tension of the cone and causes 
electrospray into the desolvation zone. A nebulizing gas (nitrogen) dries and shrinks the droplets, 
causing a build-up of positive charge at the perimeter of the droplet resulting in coulombic 
explosion of the droplets; this leads to the release of protonated analytes for entry into the 
quadrupole. The MS quadrupole separates analytes based on their mass to charge ratio (m/z) and 
then a detector detects the mass.   Mass peak data was observed at 2.992, 5.778 and 7.112 min for 
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UNBC 152-3 (7). It should be noted that the delay in time for peaks observed in the ESI in 
comparison to the HPLC is due to a physical limitation of the system. The analyte is detected first 
in the variable wavelength detector (VWD) before traveling into the LRESI-MS for ionization and 
detection.   An addition peak was observed at 8.224 min and tailed beyond 11.866 min. VLA9 (7) 
had three dominant mass peaks, two of which were broad. Peaks were found at 4.154, 7.197, 8.107 
and 9.859 min. 
 
 
 
Figure 2.2.4.2. Low resolution ESI-MS comparison of UNBC152-3 (7) and VLA9 (7). Ions 
from 100 to 1000 m/z were analyzed. Analytes were chromatographed with a phenyl-hexyl 4.6 
x 250 mm column using a gradient solvent system (80:20 acetonitrile: H2O to 100% acetonitrile 
in 10 min; flow rate of 1 mL/min). 
 
The first peak for UNBC152-3 (7) at 2.992 was a DMSO solvent peak as indicated by a 
[M2+H]+ of 157.1 m/z (Figure. 2.2.4.3). The peak at 5.778 min had a [M+H]+ peak of 300.0 which 
is the mass of the protonated form of 3 (299.16 g/mol); this indicated that not all of the reactants 
were consumed in the production of UNBC152-3 (7). Peaks at 7.112 and 8.224 min had a [M+H]+  
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of 535 m/z. The 535 m/z correlates to a protonated form of 7, which normally has a molecular 
weight of 534.44 g/mol. The data suggested the presence of two stereoisomers of 7 were produced 
in the UNBC152-3 batch. Additionally, a m/z of 471.1 was detected at 7.818 min in the ESI scans; 
this suggested the potential presence of a fused dispiropiperazine such as 8 or 9 (Figure. 2.2.4.3).  
 
Figure 2.2.4.3. Ion analysis of the dominant peaks in the UNBC152-3 (7) sample by low 
resolution ESI-MS. Analytes were chromatographed with a phenyl-hexyl 4.6 x 250 mm column 
using a gradient solvent system (80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; flow 
rate of 1 mL/min). 
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Although the abundance of the 471.1 m/z peak was at low levels, it was still detectable. 
The finding was congruent with what was reported in the Haddad article; that the 3 component 
1,3-dipolar cycloaddition reaction may produce the fused dispiropiperazine side products 8 and 
9.77 
In comparison, VLA9 (7) contained trace amounts of the 300.0 m/z peak which also 
indicated an incomplete consumption of starting reactants (Figure. 2.2.4.4). Closer analysis of the 
peaks at 7.197, 8.107 and 9.859 min indicated presence of compound 7 (535 m/z). 
 
 
Figure 2.2.4.4. Ion analysis of the dominant peaks in VLA9 (7) by low resolution ESI-MS. 
Analytes were chromatographed with a phenyl-hexyl 4.6 x 250 mm column using a gradient 
solvent system (80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; flow rate of 1 mL/min). 
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As there were three peaks found in VLA9 (7) which ionized to a mass of 535 m/z, it 
suggests the formation of three different isomers of 7. This finding was also congruent with 
Haddad’s article which stated that different time and temperature modifications to the 1,3-dipolar 
cycloaddition may produce upwards of three stereoisomers of 7.77 
2.2.4.2. Temperature Dependency of the Synthesis of SPOPP (8) 
 
To determine if temperature could influence the formation of the biologically-active 
component of the SPOPP (8) reaction mixture, multiple batches were synthesized (Table. 2.1.1.). 
The crude reaction mixtures, which contained the unpurified versions of 8 (SPOPP) and 9 were 
analysed using HPLC and low resolution LRESI-MS. A VWD 265 nm scan of VLA37 (8/9), a 
batch synthesized at 35°C temperature, indicated several notable peaks at 2.792, 3.418, 3.686, 
7.615, 8.522, 9.531 and 10.286 min (Figure. 2.2.4.5A.). Interestingly, the peak at 3.686 min was 
also found in the UNBC152-3 (7) sample (Figure. 2.2.4.1.). Four peaks, starting from 7.615 
min, were all successfully ionized for LRESI-MS after protonation using 0.1% formic acid 
(Figure. 2.2.4.5B.).  Closer analysis of the LRESI-MS spectrum indicated that all 4 peaks had a 
m/z 471.1 which matched the [M+H]+ form of 8/9 (Figure. 2.2.4.6.). The peaks were all well 
resolved by the phenyl-hexyl column using the gradient solvent system which suggested that the 
peaks were different isomers of each other. 
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Figure 2.2.4.5. HPLC-MS analysis of crude VLA37 (8/9). (A) HPLC scan at VWD 265 nm, 
B) low resolution ESI-MS trace; scan from 100 to 1000 m/z. Analytes were chromatographed 
with a phenyl-hexyl 4.6 x 250 mm column using a gradient solvent system (80:20 acetonitrile: 
H2O to 100% acetonitrile in 10 min; flow rate of 1 mL/min). 
 
This finding was not congruent with the report by Haddad, who indicated that only two 
fused dispiropiperazines will form from the dimerization reaction.77 Although it is true that there 
would be steric hinderance between the naphthalene ring and the pyrrolidine, making the formation 
of 8ʹ and 9ʹ unfavorable, this does not mean the regioisomers are impossible to form in small 
quantity under different reaction conditions (Figure. 2.2.3.1).77  
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Figure 2.2.4.6. Ion analysis of the dominant peaks in the VLA37 (8/9) sample by low 
resolution ESI-MS. Analytes were chromatographed with a phenyl-hexyl 4.6 x 250 mm column 
using a gradient solvent system (80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; flow 
rate of 1 mL/min). 
 
Given that time and temperature variations affected the ratio of regio- and stereoisomers 
of 7 produced in the 1,3-dipolar cycloaddition, further syntheses of 8 were also conducted to probe 
similar potential effects. The reaction time (3 h) was not changed during this evaluation, but the 
reaction temperature was varied. Peaks relating to products with the correct m/z were seen at 7.3 
min and beyond with the phenyl-hexyl separation (Figure. 2.2.4.7.). With the increase in 
temperature from 35 °C to 55 °C, early retention time peaks were reduced in magnitude relative 
to the major peak at 7.3 min. From the result, it was found that higher temperatures caused the 
formation of more compounds with m/z of 471.1. The peak at 7.3 min remained the dominant one 
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at 55 °C and was hypothesized to be 8, as that was the major product reported in the Haddad 
article.77  
 
 
 
Figure 2.2.4.7. HPLC spectral analysis on the effect of temperature variance for the 
synthesis of 8. Absorbance was monitored at 265 nm. Analytes were chromatographed using a 
phenyl-hexyl 4.6 x 250 mm column with a gradient solvent system 80:20 acetonitrile: H2O to 
100% acetonitrile in 10 min; flow rate of 1 mL/min). 
 
Table 2.2.4.1. Time and temperature dependent yield of 8 and NP6A according to area 
on VWD chromatogram. 
Name Time (h) Temperature 
(°C) 
% Product (8) % Product 
(NP6A) 
VLA161 24 25 22 6 
VLB135 3 35 30 15 
VLA175 3 45 38 9 
VLB133 3 55 56 11 
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2.2.5. Isolation of SPOPP (8) and NP6A 
 
In order to confirm the assumptions made by the HPLC and LRESI-MS analysis of the 
crude reaction mixtures described above, the development of an isolation procedure for the 
compounds of interested was undertaken. The purification of several batches of the reaction 
mixture (VLB133; 8/9) began by flash chromatography as the initial step (Figure. 2.2.5.1.). Crude 
material was dry-loaded into the column due to solubility issues.  
 
Figure 2.2.5.1. Purification schematic for the isolation of 8 and NP6A. 
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Three column purifications were performed and a total of 686 mg of crude material was 
processed. Since the 1 ethyl acetate: 2 hexanes system was able to separate a yellow and an orange 
compound on TLC, the system was then adapted for column purification (Figure. 2.2.3.2.). The 
hexanes amount was changed to 90% to increase the retention time of the products and to ensure 
better separation between the orange and yellow compound, believed to be 8 and 9. NP6A (yellow 
solid, 120 mg) and SPOPP (8, orange solid, 280 mg) were retrieved from the column and dried 
under reduced pressure (Table. 2.2.5.1.). 
Table. 2.2.5.1. Purification of VLB133 by FCC normal phase. 686 mg of crude material was 
invested and was purified using 50g silica. Solvent system used was 1 ethyl acetate: 9 hexanes. 
Name Elution Volume (mL) Milligrams Percent Yield % 
NP6A 320-405 120 17.5 
NP6B (SPOPP;8) 560-830 280 40.7 
 
The low percent yield after this step was not surprising considering there were multiple other peaks 
in the HPLC chromatogram of VLB133 (8/9, Figure. 2.2.4.7.). HPLC analysis determined that 
NP6A was 87% pure according to peak area (Figure. 2.2.5.2A.).  
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Figure 2.2.5.2. HPLC spectral analysis of NP6A. (A) Post FCC purification. (B) Post HPLC 
purification Absorbance was measured at 265 nm. Analyte was chromatographed with a phenyl-
hexyl 4.6 x 250 mm column using the gradient solvent system (80:20 acetonitrile: H2O to 92:8 
acetonitrile: H2O in 6 min; flow rate of 2 mL/ min). 
 
After purification by HPLC the semi-purified sample was increased to 97% purity (Figure. 
2.2.5.2B.). LRESI-MS determined the purified compound to have a [M+H]+ mass of 471 (Figure. 
2.2.5.3.). A sample was sent for high-resolution NMR analysis (600 MHz) to determine the identity 
of the molecule. 
 
Figure 2.2.5.3. Ion analysis of the purified NP6A by low resolution ESI-MS. Analyte was 
chromatographed with a phenyl-hexyl 4.6 x 250 mm column using the gradient solvent system 
(80:20 acetonitrile: H2O to 92:8 acetonitrile: H2O in 6 min; flow rate of 2 mL/ min). 
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Initially, the purification of NP6B was performed directly on the HPLC from the crude 
material, VLB133 (8/9, Figure. 2.2.5.1.). Crude material was solubilized in 80 % acetonitrile and 
syringe filtered with a 0.2 μm filter. Material was subsequently injected (100 μL per round) into 
the HPLC. After a total of 345 HPLC purification rounds, 28.7 mg of purified material was 
obtained. Secondary HPLC analysis of the combined fractions suggested 99 % purity (Figure. 
2.2.5.4A.). A LRESI-MS scan from 100 to 1000 m/z only displayed a singular dominant peak, 
which further supported the conclusion that the sample was of high purity (Figure. 2.2.5.4B.). 
A 
 
B 
 
Figure 2.2.5.4. HPLC-LRESI-MS analysis of purified SPOPP (8). (A) Absorbance measured 
at 265 nm. (B) Mass was detected from 100 to 1000 m/z. Analyte was chromatographed with a 
phenyl-hexyl 4.6 x 250 mm column using the gradient solvent system (80:20 acetonitrile: H2O 
to 100% acetonitrile in 6 min; flow rate of 2 mL/ min). 
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Analysis of the mass scan at 4.001 min showed the ions of 471.2, 472.2, 473.2 and 236.1 
(Figure. 2.2.5.5.). The m/z of 471.2 correspond to the [M+H]+ ion while the 236.1 corresponds to 
the [M+2H]+ ion. The compound was sent for structural analysis to confirm its identity. Since the 
purity was greater than 95%, it was also assessed for biological activity. SW480 colorectal cancer 
cells treated with SPOPP (8) revealed favorable bioactivity as determined by Western blot and, 
MTT assay analyses. More details will be discussed in Chapter 3. 
 
Figure 2.2.5.5. Ion analysis of the purified SPOPP (8) by low resolution ESI-MS. 
 
2.2.6. Purification of Other Peaks in the SPOPP (8) Mixture 
2.2.6.1. Initial Purification and Analysis 
The HPLC chromatograms (VWD 265 nm) of the crude synthetic batches of 8 (VLA175, 
VLB133 & VLB135), showed that there were other compounds present that did not correspond to 
8 or isomers of 8 (Figure. 2.2.4.7.). The original bioactive sample UNBC152-3 (7) also contained 
additional peaks that did not correspond to these expected products either (Figure. 2.2.4.1.). One 
peak of interest, which had a retention time of 3.7 min on the phenyl-hexyl column separation, was 
found to be common to both UNBC152-3 (7) and for all synthetic batches of 8 (Figure. 2.2.4.1. 
and 2.2.4.7.) and we decided to investigate these compounds further.   
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To this end, crude VLA37 (8/9) was fractionally separated using a C18 matrix and fractions 
were collected based on the color of the band on the column. The crude was separated using the 
same flash column as previously described for the separation of 8 and 9. C18 silica was packed 
into the column using 100% isopropanol and the column was equilibrated with 5 column volumes 
of the solvent system, 8 H2O: 2 methanol: 4 acetonitrile: 0.25 acetic acid. Following equilibration, 
crude material (200 mg) was dry-loaded with 2 g of C18 silica. Fraction 1 (F1) was eluted in the 
first 30 mL and the solution was placed in a round bottom flask (Figure. 2.2.6.1).  
 
Figure 2.2.6.1. Purification schematic to produce fraction 1 (F1) components of crude 8/9. 
 
The solvent was removed under reduced pressure to produce a reddish-brown powder (21 
mg, 10%) (Figure. 2.2.6.2A.). Subsequent fractions were also collected in blocks of 30 mL 
portions. Naming of the fractions follows the convention of VLBX-Y, where X is numbered after 
the page number the experiment was recorded on and Y is numbered after the fraction number.  
On TLC, F1 was not identified as a pure compound, however, it did have a dominant spot at a Rf 
of 0.23 (Figure. 2.2.6.2B.). 
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Figure 2.2.6.2. Reverse phased (C18) fractionation and TLC analysis of VLA37 (8/9). (A) 
Approximately 50 mL fractions. (B) TLC of fractions.  FCC solvent system used was 4 
acetonitrile: 2 methanol: 8 H2O: 0.25 acetic acid; TLC solvent system for analysis was 7 ethyl 
acetate: 2 methanol: 1 H2O: 0.25 acetic acid. Visualization was done with long wave UV. 
 
HPLC analysis of VLA37-1 using VWD at 264 nm revealed that the sample had 2 major 
peaks at 2.370 and 2.588 min (Figure. 2.2.6.3A). The peaks, however, were not well ionized in the 
LRESI-MS, and only one mass peak seen was at 2.850 min (Figure. 2.2.6.3B.). This peak had a 
m/z of 157.1, which was the DMSO solvent peak commonly found as the [M2+H]+ ion (Figure. 
2.2.6.4.). The sample was originally dissolved in DMSO for biological testing, so this finding was 
not unexpected. VLA37-1 demonstrated pronounced biological activity in terms of abrogating the 
IMP-1-KRAS mRNA interaction (Chapter 3, section 3.3.1.). The fraction also displayed activity 
in lowering KRAS protein expression for SW480 human colorectal cancer cells. The sample was 
consumed quickly from biological testing and further F1 samples were produced to see if the 
bioactivity was repeatable and to generate more material (VLA159, VLB135 & VLB187) for 
subsequent purifications.  
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Figure 2.2.6.3. HPLC-LRESI-MS analysis of VLA37-1. A) VWD 265 nm, B) MS abundance 
scan from 100 to 1000 m/z. The analyte was chromatographed with a phenyl-hexyl 4.6 x 250 
mm column using a gradient system (80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; 
flow rate of 1 mL/min).  
 
 
Figure 2.2.6.4. Ion analysis of the dominant peak in VLA37-1 fraction by LRESI-MS. The 
analyte was chromatographed with a phenyl-hexyl 4.6 x 250 mm column using a gradient system 
(80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; flow rate of 1 mL/min). 
 
A subsequent yellow-colored fraction (F2) contained a dominant TLC spot at a Rf of 0.9 
(Figure. 2.2.6.2B). Fractions containing the dominant yellow compound were pooled together and 
further purified using preparative TLC (9 hexanes: 1 ethyl acetate). The band containing the yellow 
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compound was scraped from the TLC, extracted with 100% acetonitrile, filtered, and dried under 
reduced pressure. The newly dried product was named NP4.  NP4 contained two dominant peaks: 
one at 2.485 min and one at 3.7 min (Figure. 2.2.6.5A.). The only peak which ionized in this sample 
was also the DMSO solvent found at 2.850 min (Figure. 2.2.6.5B.).  
A 
 
B 
 
Figure. 2.2.6.5. HPLC-MS analysis of NP4. A) VWD 265 nm, B) MS abundance scan from 
100 to 1000 m/z. The analyte was chromatographed with a phenyl-hexyl 4.6 x 250 mm column 
using a gradient system (80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; flow rate of 1 
mL/min). 
 
At approximately, 3.9 min of the LRESI-MS spectra, an ion of 250.1 and 251.1 was found 
(Figure. 2.2.6.6.). Since NP4 was found at 3.7 min, and a similar peak was observed at the same 
retention time in the original analysis of UNBC152-3 (7), it was hypothesized that this compound 
could represent a common side product in both reactions. The identity of the compound is currently 
unknown, however, FP assay determined that NP4 significantly lowered IMP-1 percent bound to 
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KRAS-FL probe but caused total fluorescence to increase by 289 % (section 3.3.1.) NP4 also 
displayed modest bioactivity in SW480. The complications of NP4 presence will be discussed 
later. 
 
Figure 2.2.6.6. Ion analysis of NP4 from LRESI-MS. Analyte was chromatographed with a 
phenyl-hexyl 4.6 x 250 mm column using the gradient solvent system (80:20 acetonitrile: H2O 
to 100% acetonitrile in 10 min; flow rate of 1 mL/ min). 
 
2.2.6.2. F1 Sample Production as a Means for Comparison 
  Various other batches of F1 were also obtained from the temperature dependent 
experiments mentioned previously (section 2.2.4.) Several were also synthesized at 35 °C to 
determine reaction reproducibility (Table 2.2.6.1.). The C18 purification of crude samples was 
repeated to see possible differences in peak profile data on both the HPLC and LRESI-MS ions. 
Various F1 samples were produced by FCC C18 purification as previously mention and analyzed 
by both HPLC and LRESI-MS (Table 2.2.6.1.). The F1 samples, VLB188-1 and VLB189-1 were 
purified from crude batches, VLB187 (8/9) and VLA161 (8/9) respectively. VLB187 (8/9) was 
synthesized at 35 °C for 1.5 h and VLA161 (8/9) was synthesized at 25 °C for 24 h. Similar peaks 
were seen from the HPLC traces of VLB165-1, VLB159-1, VLB188-1 and VLB189-1 (Figure. 
2.2.6.7). The peak at approximately 3.7 min, which corresponded to NP4, can be seen for all four 
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samples, regardless of time or temperature variation in the prior synthesis step. The only difference 
between the synthesis variants was the relative intensity for the peak at 2.940 min; this peak was 
the largest relative to the others for the 24 h synthesis at room temperature (Figure. 2.2.6.7D). 
A) B) 
  
C) D) 
  
Figure 2.2.6.7. HPLC trace comparison of various fraction 1 samples from C18 FCC 
purification of crude batches of 8. A) VLB165-1, B) VLB159-1, C) VLB188-1, 1.5H, D) 
VLB189-1 RT, 24H. Crude batches were synthesized at 35°C for 3 h unless otherwise stated. 
The analyte was chromatographed with a phenyl-hexyl 4.6 x 250 mm column using a gradient 
system (80:20 acetonitrile: H2O to 100% acetonitrile in 10 min; flow rate of 1 mL/min). 
 
The presence of noteworthy ions was recorded and the results were compared across all 
main samples (Table 2.2.6.1.). The [M+H]+ m/z ion of 183 was tracked due to the initial presence 
in Dr. Yeong Keng Yoon’s LC-MS analysis of the UNBC152 (7) batches. The 199 and 200 m/z 
ions were hypothesized to be 1,8-naphthalic anhydride (198.174 g/mol) which is the oxidized 
version of acenaphthenequinone (4); this ion was found in both samples of the 
acenaphthenequinone (4) reagent purchased from Sigma-Aldrich and Alfa Aesar. Presence of 199 
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m/z in the F1 fractions would then suggest remaining unreacted material. The 250 m/z ion was 
found in almost all the F1 fractions, as well as both UNBC152-3 and UNBC142; this indicated 
that NP4 was present. UNBC142 was another library compound in the 1,3-dipolar cycloaddition 
series. The synthesis of UNBC142 involved similar reagents to those found for UNBC152 (see 
section 2.1.3.) but the dipolarophile was different. It originally was used by Ms. Chuyi Wang as a 
negative control for the cellular bioassays.  
Table 2.2.6.1. Comparison of notable ions found by LRESI-MS analysis of F1 samples of 
8 as compared to the collaborator’s UNBC152-3 (7) Presence of ion is indicated by the letter 
Y while not detectable is indicated by N. Numbers before Y indicate more than 1 occurrence of 
the specified ion. 
 
 
All F1 components were kept in semi-crude form when testing for biological activity with 
respect to the IMP-1-KRAS mRNA interaction; this was strategically done to determine if the sum 
of all the side products were able to interrupt the protein-RNA interaction. Although testing crude 
is not optimal, the original UNBC152-3 (7) was found in its crude form. The semi-crude F1 
fraction would serve as a basis for comparison against the original UNBC152-3 (7).  F1 was found 
to inhibit the IMP-1-KRAS mRNA interaction as found by FP assay (Chapter 3, Figure. 3.3.3.). 
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Additionally, various F1 samples lowered cellular proliferation of SW480 CRC as determined by 
MTT assay (Figure. 3.3.10.). Given this result, purification of the F1 samples were investigated to 
determine if it was possible to purify further and perhaps increase bioactivity.  
2.2.6.3. HPLC Optimization of Fraction 1 Mixtures 
 
 F1 samples were purified further on the phenyl-hexyl column to determine if the most 
abundant peak was contributing to the observed biological activity (Figure. 2.2.6.8.). Batch 
VLB188-1 was used to optimize purification procedures. The solvent system was modified in 
order to better separate and retain the fast-eluting peaks observed when using the 80-92 % 
acetonitrile in H2O gradient (0 to 6 min) system. Initially, the solvent system was reduced to 50:50 
acetonitrile: H2O, increasing to 70:30 acetonitrile: H2O over a period of 6 min. By reducing the 
percentage of acetonitrile, the eluting compounds were expected to better interact with the 
hydrophobic phenyl-hexyl matrix of the column. Additionally, 0.2% formic acid (aq) was used as 
an additive to neutralize anionic molecules or protonate basic molecule, with the goal of potentially 
changing column selectivity. If by protonation, some compound became more neutral, the 
retention time would then increase and would cause better separation. The change in solvent 
system led to better retention of compounds (Figure. 2.2.6.8B.). 
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Figure 2.2.6.8. HPLC optimization of the purification of VLB188-1. (A) 80:20 acetonitrile: 
H2O to 100% acetonitrile in 10 min; flow rate 1 mL/min, (B) 50:50 acetonitrile: H2O to 70:30 
acetonitrile: H2O in 6 min; 0.2% FA; flow rate 0.7mL/min. (C) Acenaphthenequinone (50:50 
acetonitrile: H2O to 70:30 acetonitrile: H2O in 6 min; 0.2% FA; flow rate 0.7mL/min.). Analytes 
were chromatographed with a phenyl-hexyl 4.6 x 250 mm column. 
 
A large peak was seen at 2.936 min with several smaller peaks at 4.242, 5.844 and 8.095 
min. Fraction-collection of the peaks at 2.936 and 4.242 min became the focus for this part due to 
their abundance. The other peaks were not collected due to the lower abundance. As another 
purification check, the retention time of acenaphthenequinone (AcQ) was analyzed under the same 
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solvent system. Presence of AcQ would be problematic in the bioassays due to its previously 
reported bioactivity in A549 lung cancer cells.79 AcQ was found to be retained at 8.676 min in the 
new solvent system conditions and was safely excluded from the purification process (Figure. 
2.2.6.8C.). The flow rate at 0.7 mL per min was increased to 1.0 mL per min to increase acquisition 
rate without decreasing peak separation (data not shown). As seen in Figure 2.2.6.9., the 
purification process for VLB188-1 was only moderately successful. Fraction 1 (VLB188-1.1) of 
the newly collected sample contained one dominant peak at 1.933 min and was a total peak area 
of 82 % (Figure. 2.2.6.9A.). The peak did not have a gaussian distribution which may indicate 
presence of other over-lapping peaks. Smaller peaks can be seen at 2.917 min and beyond but the 
total area of the peaks only totaled to 18 %. Fraction 2 (VLB188-1.2) and 3 (VLB188-1.3) have 
more peaks compared to VLB188-1.1 (Figure. 2.2.6.9.). 
 
 
 
 
 
 
 
 
 
68 
 
A 
 
B 
 
C 
 
Figure 2.2.6.9. HPLC trace of fractionated VLB188-1. A) Fraction 1, B) Fraction 2, C) 
Fraction 3. Analytes were chromatographed using a phenyl-hexyl 4.6 x 250 mm column using 
a gradient solvent system (50:50 acetonitrile: H2O to 70:30 acetonitrile: H2O in 6 min; 0.2% FA; 
flow rate of 1.0 mL/min). 
 
Collection of the regions encompassing the peaks originally found at 2.936 and 4.242 min, 
caused enhancement of previously unseen peaks and further refinement of the fractions was halted 
due to a shift in experimental priorities. The stability of these compounds was also questionable 
since there was a chance that these were merely intermediates in producing the fused piperazines 
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8 and 9. Regardless, these samples were also tested for possible biological activity. MTT assay 
determined that the more purified fractions such as VLB188-1.1 had reduced activity as compared 
to the semi-purified F1 form (Figure. 3.3.11.). In light of this, the pursuit in the further refinement 
of F1 was lowered in experimental priority. 
2.2.7. Structural Characterization 
2.2.7.1. (2E)-2-(2-bromobenzylidine)-1-indanone (3) 
2.2.7.1.1. Analysis 
The 1H-NMR spectra of 3 matches the 1H-NMR spectra reported previously by Martinez 
et al. (Figure. 2.2.7.1.).80 The peak at 3.99 ppm corresponded to the CH2 proton located on the 
indanone ring. Eight aromatic protons can be found from 7.30 to 7.72 ppm. The vinylic proton was 
was found at 8.01 ppm and is overlapping a signal from an Ar-H proton. The peaks at 3.52, 1.73, 
1.29 and 0.90 ppm all integrated to less than 1, which indicated the presence of minor 
contaminants. The peak at 3.52 ppm corresponded to methanol. The two peaks at 1.29 and 0.90 
ppm corresponded to hexanes. The peak at 1.73 ppm is unknown. Since the spectra of 3 matches 
the 1H-NMR spectra as reported previously by Martinez et al., no further analysis was pursued in 
this case. 
2.2.7.1.2. NMR Spectrum 
Ivory colored thin needles; Rf = 0.58 (1 Ethyl acetate: 2 hexanes); Molecular formula of 
C16H11OBr; LRESI-MS [M+H]+ m/z of 300; 1H-NMR (300 MHz, CDCl3) δ = 3.99 (s, 2H, CH2), 
7.30 (m, 1H, Ar–H), 7.43–7.72 (m, 6H, Ar–H), 8.00 (d, 1H, J = 7.6 Hz, Ar–H), 8.01 (s, 1H, HC=C). 
70 
 
 
Figure 2.2.7.1. 1H-NMR spectra of (2E)-2-(2-bromobenzylidene)-1-indanone (3). Sample 
was dissolved in CDCl3 and processed at 300 MHz. 
 
2.2.7.2. SPOPP (8) 
2.2.7.2.1. Analysis 
 The SPOPP (8) structure (Figure. 2.2.7.2) contains an axis of symmetry, which is 
demonstrated in the 1H-NMR spectra. The heterocyclic protons adjacent to N on C14/25 and 
C12/28 were the most uniquely identified for this structure. Due to the stereocenters at the 
piperazine rings, the pyrrolidine ring residues shared different integration values for the CH2 
groups.  Due to the proximity to the aromatic ring system, H-12/28 (2 x CH for each) are slightly 
more de-shielded and found at 2.15 and 2.6 ppm. H-14/26 (2 x CH) were the most de-shielded due 
to proximity to the nitrogen atom. H-15 (CH2) and H-30 (CH2) are proximal to H-14 and H-26 
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which caused a slight shift to 1.97 and 1.7 ppm. H-11 (CH2) and H-29 (CH2) were the least de-
shielded and were found at 1.78 and 1.61 ppm.  
 
Figure 2.2.7.2. Numbered positions for the structure of SPOPP (8). 
 
 The 13C-NMR displayed a peak at 207.3 ppm which indicated the presence of the carbonyl 
carbons of C-35 and C-33. From 119.4 to 141.4 ppm are the signals for the aromatic carbons found 
for the naphthalene rings. Since these rings is equivalent, only 10 peaks were visible for the 20 
total carbons. The distinguishing signals in this case were the aliphatic signals located at 72.3, 
60.5, 47.6, 27.9 and 21.3 ppm. Due to the axis of symmetry, the spectra only displayed 5 peaks 
out of the possible 10 carbon signals.  
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Table 2.2.7.1. Chemical shifts of protons and carbons for SPOPP (8). 
Position 1H Shifts (ppm) 13C Shifts (ppm) 
1, 21 7.18 127.98 
2, 20 7.38 124.8 
3, 19 - 130.16 
4, 18 - 141.4 
5, 33 - 136.16 
6, 16 7.46 123.28 
7, 25 7.67 130.77 
8, 24 7.43 127.68 
9, 23 7.65 119.4 
10, 22 - 134.09 
11, 29 1.61, 1.78 21.3 
12, 28 2.15, 2.6 47.6 
14, 26 3.89 60.5 
15, 30 1.7, 1.97 27.9 
31, 32 - 72.3 
35, 33 - 207.3 
 
C-31 and C-32 were located at 72.3 ppm due to their position in relation to both the nitrogen atom 
and the carbonyl. C-14 and C-26 were found at 60.5 ppm, which is congruent with the de-shielding 
by the nitrogen atom found in the 1H-NMR. C-12 and C-28 were found at 47.6 ppm due to 
proximity to the nitrogen atom. C-15 and C-30 were located at 27.9 ppm. C-11 and C-29 were the 
most shielded and was found at 21.3 ppm. 
Homonuclear correlation spectroscopy (COSY) was performed to determine proton-proton 
coupling by neighboring protons (Figure. 2.2.7.5.). Correlations were observed between protons 
at 3.89 ppm (H14/26) peak, those at 1.97 ppm and 1.7 ppm (H15/30. The protons at 2.6 ppm 
(H12/28) correlated to 1.78 ppm (H11/29) and 2.15 ppm (H12/28). The peak at 2.15 ppm (H12/28) 
also correlated to those at 1.78 ppm (H11/29). The protons at 1.97 ppm (H15/30) correlated to 
those at 1.7 ppm. The protons at 1.78 ppm correlates to those at 1.61 ppm. Although this spectrum 
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identifies both geminal and vicinal coupling interactions, the absolute stereochemistry of the 
molecule cannot be explicitly determined. Given that there are two pyrrolidine rings for the 
dispiropiperazine isomers, the maximum proton signals for the aliphatic hydrogens would be seven 
if the protons were all shielded differently. There are seven visible signals between 1.69 to 3.98 
ppm which indicated some symmetry. However, a truly symmetrical molecule would have only 
four proton signals between 1.69 to 3.98 ppm; the integration values for the protons would also be 
twice the value due to overlapping signals. In this case, most of the proton signals have an 
integration value of approximately 2. Haddad et al also indicated that the more symmetrical 
isomers, 8ʹ and 9ʹ, would have these overlapping signals for the aliphatic region (Section 2.2.3.).77 
Haddad et al. required x-ray diffraction to solve the structure of 8 and thus the technique might be 
necessary to solve this structure.77 Regardless, the 1H-NMR spectrum of SPOPP matches what is 
reported in the literature as compound 8. 
Heteronuclear single quantum correlation experiment (HSQC) determined correlation 
between the aliphatic protons from the 1H-NMR spectra and the 13C-NMR spectra for SPOPP (8, 
Figure. 2.2.7.6.). The H14/26 protons at 3.89 ppm were found correlated with the carbon signal at 
60.5 ppm. Due to a degree of symmetry, the three carbon signals at 47.6, 27.9 and 21.3 ppm each 
correlated to two proton signals. The carbon signal at 21.3 ppm correlates with H11/29. The carbon 
signal at 27.9 ppm correlates with H15/30. The carbon signal at 47.6 ppm correlates with H12/28.  
2.2.7.2.2. NMR Spectrum 
Orange powder; Rf = 0.33 (1 Ethyl acetate: 9 hexanes, ran twice); LRESI-MS [M+H]+ m/z 
of 471 1H-NMR (600 MHz, CDCl3) δ = 7.17−7.68 (m, 12H), 3.89 (m, 2H), 2.59−2.62 (m, 2H), 
2.13−2.17 (m, 2H), 1.96−2.01 (m, 2H), 1.69−1.82 ppm (m, 6H); 13C-NMR (125 MHz, CDCl3) δ 
74 
 
= 141.42, 136.86, 134.07, 130.76, 130.18, 127.93, 127.68, 124.81, 123.30, 119.35, 72.30, 60.54, 
47.63, 27.89, 21.31 ppm. 
 
Figure 2.2.7.3. 1H-NMR spectra of SPOPP (8). Sample was dissolved in CDCl3 and processed 
at 600 MHz. 
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Figure 2.2.7.4. 13C-NMR spectra of SPOPP (8). Sample was dissolved in CDCl3. 
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Figure 2.2.7.5. COSY spectra of SPOPP (8). Sample was dissolved in CDCl3. 
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Figure 2.2.7.6. HSQC of SPOPP (8). Sample was dissolved in CDCl3. 
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2.2.7.3. NP6A 
 
2.2.7.3.1. Analysis 
 The spectra of NP6A is different from what was reported in the literature for compound 9 
(Figure. 2.2.7.7.). Initially, we hypothesized that NP6A was compound 9, based on the LRESI-MS 
data and the report by Haddad.77 Upon NMR analysis of NP6A, however, several discrepancies 
were identified. The aromatic signals of NP6A were much more symmetrical than those observed 
for 9 (Figure. 2.2.7.8.). Three clusters of peaks, each integrating to 4, can be seen for NP6A, which 
is not the case for compound 9 (Figure. 2.2.7.7.). The peak observed at 4.0 ppm for 9 is not present 
in NP6A, however, NP6A was observed to have a slightly more downfield peak at 4.88 ppm 
(Figure. 2.2.7.7.). The peak at 7.26 ppm was due to the residual solvent signal of CDCl3 while the 
peak at 0.0 ppm was the TMS standard. Ten signals could be found within the aromatic region for 
13C-NMR which still indicated the symmetrical naphthalene rings of the fused piperazine (Figure. 
2.2.7.9.). The difference was the aliphatic region, which only contained 4 carbon peaks as 
compared to the 13C-NMR for 9 which contained 5 (Figure. 2.2.7.10.). Unfortunately, the COSY 
spectrum of NP6A did not give enough information to correctly identify which regioisomer it was 
(Figure. 2.2.7.11.). Additional spectral analysis might not correctly lead to the solution of the 
NP6A structure. According to Haddad, x-ray diffraction was utilized to differentiate between 8 
and 9. Solving NP6A might require the same technique.  
2.2.7.3.2. NMR Spectrum 
Yellow powder, Rf = 0.53 (1 ethyl acetate: 9 hexanes, resolved twice on the same TLC); 
LRESI-MS [M+H]+ m/z of 471. 1H-NMR (300 MHz, CDCl3) δ = 8.14-8.16 (m, 4H), 7.76-7.93 
(m, 4H), 7.74-7.76 (m, 4H), 4.88 (m, 2H), 2.45-2.55 (m, 4H), 1.37-1.53 (m, 7H), 0.56-0.58 (m, 
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2H). 13C-NMR (125 MHz, CDCl3) δ = 208.89, 141.95, 140.84, 132.22, 131.74, 130.29, 128.70, 
128.04, 124.45, 121.61, 120.58, 60.67, 60.60, 46.12, 24.80. 
 
Figure 2.2.7.7. 1H-NMR spectra of NP6A. Sample dissolved in CDCl3 with 0.3% TMS and 
processed at 300 MHz. 
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Figure 2.2.7.8. 1H-NMR spectra of 9. Sample dissolved in CDCl3 and processed at 300 
MHz..77 
 
81 
 
 
Figure 2.2.7.9. 13C-NMR spectra of NP6A. Sample dissolved in CDCl3 with 0.3% TMS. 
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Figure 2.2.7.10. 13C-NMR spectra of 9. Sample dissolved in CDCl3 with 0.3% TMS.77 
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Figure 2.2.7.11. COSY of NP6A. Sample dissolved in CDCl3 with 0.3% TMS. 
 
2.2.8. Summary 
 
 The original goal of replicating UNBC152-3 (7) changed drastically with the discovery of 
the side product 8. The combination of TLC, HPLC and LRESI-MS suggested that the original 
UNBC152-3 contained 8. Additionally, FP analysis led us to focus on crude 8 due to its enhanced 
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activity at reducing the percentage of IMP-1 binding to KRAS-FL. Purifications of the crude 
dispiropiperazine mixture containing 8 resulted in the retrieval of both 8 and a structurally 
unknown isomer called NP6A. The result was surprising since NP6A did bear the same yellow 
coloration of 9 as described in the Haddad et al. article.77 Additional experiments are required to 
elucidate the structure of NP6A; perhaps X-ray diffraction or nuclear overhauser effect 
spectroscopy (NOESY) could be used. If the results are positive, NP6A would represent a new, 
unreported dispiropiperazine derivative that can be generated from a one-pot synthesis. The 
purification of other side products generated by the synthesis 8 did not result in generating a more 
bioactive molecule. These side products could not be purified further by HPLC; this could be a 
result of the side products being unstable. Regardless, NP6A and 8 were isolated and a detailed 
analysis of their bioactivity is discussed in Chapter 3.  
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Chapter 3 
 
Biochemical Characterization of Spiropyrrolizidine and Piperazine 
Derivatives 
 
 This chapter focuses on the biochemical analyses of the purified and semi-purified 
synthetic compounds described in Chapter 2. The bioassays performed followed the same 
techniques that were previously used by Ms. Chuyi Wang in the analysis of UNBC152-3 (7). Initial 
test with fluorescence polarization (FP) assay was aimed at determining which of the compounds 
in UNBC152-3 (7) were responsible for the reduction in FP. The crude mixture of 
dispiropiperazines 8 and NP6A was initially used as a control to compare alongside UNBC152-3 
(7) in the FP assay. Western blot analyses were performed to determine the effects of 8, NP6A, 3, 
4, and 5 on the repression of KRAS protein expression in SW480 and HT29 human colorectal 
cancer cells.  Preliminary cellular analyses with Fraction 1 (F1) components was also explored. 
The rationale for focusing on compound 8 (SPOPP) is discussed herein. An MTT assay was 
conducted on all relevant compounds and mixtures to determine their effect on cellular 
proliferation. The rationale for this choice was that there can be a discrepancy between protein 
repression and decrease in cellular proliferation. A quantitative polymerase chain reaction was 
performed to determine steady-state mRNA levels of KRAS; this was to determine the potential 
mechanism for the repression in KRAS protein expression. Lastly, investigations into the 
biochemical mechanism of the anti-proliferative activity of SPOPP (8) were conducted using flow 
cytometry analyses. 
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3.1 Methodology – Fluorescence Polarization Assay to Assess the Effect on IMP-1-KRAS 
mRNA Interaction   
 
3.1.1. Generation of Recombinant IMP-1 
3.1.1.1 Protein Generation 
 For the fluorescence polarization assay, two truncated IMP-1 variants were generated. One 
truncation removed the N-terminal RRM1 and RRM2 motifs leaving the presence of KH1 to KH4 
domains (KH1to4) and the other truncation removed the RRM1, RRM2, KH1 and KH2 domains, 
leaving only KH3 and KH4 (KH3to4) present. The gene for the truncations was previously cloned 
into the pET41c plasmid, sequenced by Macrogen and verified using FinchTV and Serial Cloner. 
Plasmids were transformed into the calcium competent E. coli BL21 strain by heat shocking at 42 
°C. Transformed BL21 was plated on Luria-Bertani (LB) broth plates containing kanamycin (25 
μg/mL) and grown overnight. After overnight growth, approximately 100 colonies were selected 
to grow as a starter culture in 100 mL of LB-kanamycin broth for 3 h at 37 °C. The culture was 
then transferred to a Fernbach flask containing 900 mL LB-kanamycin broth for further growth. 
Once the OD600 reached 0.5, IPTG (1 M) was added to induce protein production. The culture was 
then incubated for another 4 h. Cells were then pelleted at 3000 x g for 15 min and the supernatant 
was removed. Cell pellets were then transferred to the -80 °C freezer for storage. 
3.1.1.2 Protein Purification  
 
 The cell pellets were thawed on ice and then resuspended with 12 mL Buffer B (8 M urea, 
100 mM NaH2PO4, 10 mM Tris-Cl; pH 8) for lysis. The slurry was transferred to a 50 mL conical 
tube and placed on a waver for 1 h. After incubation, the sample was pelleted at 13200 rpm for 30 
min and the supernatant was removed. The supernatant was then syringe filtered (0.45 μM) to a 
new 50 mL conical tube and 2 mL of Ni-NTA resin was added. The mixture was incubated for 1 
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h for binding. Buffer C (pH 6.5), D (pH 6.3), E (pH 5.9) and F (pH 4.5) were generated from 
Buffer B in preparation for column purification. The lysate-bounded Ni-NTA resin was added to 
a BIO-RAD Poly-Prep® column (0.8 x 4 cm). Impurities were washed with 5 mL Buffer B, 5 mL 
Buffer C and 5 mL Buffer D. Protein was then collected in 1 mL fractions upon addition of 12 mL 
Buffer E and 12 mL Buffer F. The purity of the fractions was analyzed using a 10% SDS-PAGE 
gel and visualized using Coomassie blue.  
3.1.1.3 Protein Refolding and Quantification 
 
 Approximately 1 mL of the purest protein fractions were dialyzed using the Thermo 
Scientific Slide-A-Lyzer™ dialysis cassette (3500 MWCO) in 250 mL Buffer A (200 mM NaCl, 
20 mM Tris-HCl, 1 mM GSH, 0.1 mM GSSG, 10 % v/v glycerol, 2 M urea, 0.01 % v/v Triton X-
100; pH 7.4) at 4 °C for 24 h. After 24 h, the protein was then dialyzed in 250 mL Buffer A2 (200 
mM NaCl, 20 mM Tris-HCl, 10 % v/v glycerol, 0.01 % v/v Triton X-100; pH 7.4) at 4 °C for 2 h. 
The protein was transferred to a new container with 1000 mL Buffer A2. The newly refolded 
protein was quantified using the Thermo Scientific BCA assay kit. In brief, 200 μL of reagent (1 
B: 50 A) was mixed with 10 μL protein in a Sarstedt 96-Well Tissue Culture plate and incubated 
at 37 °C for 30 min before being read at 562 nm with the BioTek® Synergy 2 plate reader.  
3.1.2. Fluorescence Polarization Assay 
 
 The KRAS probe used for fluorescence polarization analysis was purchased from Thermo 
Scientific. The sequence was derived from the coding region located between 139 to 185 nts 
(5’AUGGAGAAACCUGUCUCUUGGAUAUUCUCGACACAGCAGGUCAU-6-FL-3’). 
Additionally, the probe was fluorescein labeled at the 3’ end. Binding Buffer (50 mM Tris-Cl pH 
7.4, 12.5 mM EDTA pH 8, 25 % glycerol, 0.01 % Triton-X and ddH2O) was used in every reaction. 
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Components were added to a Thermo Scientific MicroFluor® 384-Well microplate in the 
proportion of 8 protein, 4 Binding Buffer, 3 KRAS probe and 4 inhibitor in either a 19 μL or 100 
μL reaction. Proteins were diluted to a final concentration of either 300 nM or 60 nM which 
represents ~80% bound and KRAS was diluted to either 10 or 2 nM depending on the solubility 
of the compounds that were tested. Compounds were tested from 0 to 100 μM. After addition to 
the microplate, the reaction was incubated at 37 °C for 30 min before being read on the BioTek 
Synergy 2 plate reader. Percentage bound was calculated based on the ratio of fluorescence 
anisotropy (treatment/DMSO control). 
3.2 Methodology – Analysis of Spiropyrrolizidine and Piperazine Derivatives on Human 
Colorectal Cancer Cells 
3.2.1. General Information for Cell Preparation 
 The human colorectal cancer cell lines, HT29 and SW480, were maintained in T75 flasks 
at 37 °C under 5 % CO2. The growth media used was 20 mL of Minimum Essential Medium Eagle 
(EMEM) from Lonza. In preparation for plating, cells were grown to 80 % confluency. The T75 
was washed with 7 mL Dulbecco’s Phosphate Buffered Saline (DPBS). Cells were then trypsinized 
with 2 mL Trypsin-EDTA (0.25 %) at 37°C for 5 min. Trypsinization was stopped with the 
addition of 18 mL EMEM (with 10 % Fetal Bovine Serum). A cell sample (20 μL) was stained 
with Trypan Blue and manually counted with the Bright-Line hemocytometer. Cells were then 
plated in the 6-well plate at the concentration of 30 x 104 cells per well (SW480) or 60 x 104 cells 
per well (HT29) and incubated overnight at 37 °C. Following incubation, compounds were added 
to each well to a final concentration of 10 or 20 μM with 2 % DMSO being the control. Plates 
were incubated for another 48 h before being harvested for further analysis. 
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3.2.2. Total Protein Harvesting and Western blot Detection of KRAS 
 Following the 48-h compound treatment, each well was washed twice with 1 mL DPBS. 
To each well, 150 μL of lysis buffer (150 mM NaCl, 50 mM Tris-Cl, 1 % Triton-X 100 and 0.5 % 
SDS) was added and lysed cells were transferred into 1.5 mL Eppendorf tubes (300 μL per tube). 
Acetone (4 x volume; 1200 μL) was added to each tube and tubes were transferred to the -20 °C 
freezer for overnight precipitation of protein. Following precipitation, tubes were centrifuged at 
10,000 x g for 10 min at 4 °C. Acetone was removed and the pellets were left to dry for 
approximately 15 min. Pellets in each tube were then reconstituted with 20 μL of MilliQ H2O. 
Protein was then quantified using the BCA kit as before. 
 Harvested protein (12 uL, 30 μg per sample) was boiled with 3 uL 5x SDS loading buffer 
(0.25 % Bromophenol blue, 0.5 M DTT, 50 % glycerol, 10 % SDS and 5 % β-mercaptoethanol). 
Boiled samples were loaded into a 13.3 % SDS-PAGE and was ran for 50 min at 200 V. The SDS-
PAGE was then transferred to a GE Healthcare Amersham™ Protran™ 0.45 μm nitrocellulose 
membrane. The transfer was performed at 4 °C at 100V for 1 h. Following the transfer, the 
membrane was blocked with 5 % (w/v) skim milk in TBST (0.05 M Tris-Cl, 0.15 M NaCl, 0.1 % 
Tween-20, pH 7.4) and was left on a waver overnight at 4 °C. The blocked membrane was washed 
3 times (10 min each) with TBST and incubated with anti-K-Ras mouse mAb (1:500) from Sigma-
Aldrich for 2 h. The blot was then washed 3 times as before and incubated with goat anti-mouse 
IGg secondary antibody (1:4000). The blot was washed 3 more times. Visualization was achieved 
by addition of SuperSignal™ West Fempto Maximum Sensitivity solution (1 mL) from Thermo 
Scientific. The image was acquired using the ProteinSimple FluorChem Q image and protein bands 
were quantified using the AlphaView Q software. Luminescence analysis was performed on the 
house keeping gene (HKG; thioredoxin and GAPDH) and KRAS bands. Background noise was 
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also subtracted from the target bands using the software. A ratio of luminescence for KRAS: HKG 
was calculated for each treatment including the DMSO control to determine expression values. 
The expression value for a specific treatment was divided by the expression value for the DMSO 
control to produce an expression ratio. This process was repeated for the other proteins of interest 
using the antibodies found in Table 3.2.1. 
Table 3.2.1. Summary of antibodies used in Western blot analyses. 
Name Expected 
Band Size 
(kDa) 
Species 
Origin 
Dilution Company Catalogue 
Number 
Thioredoxin 12 Rabbit 1:2000 Abcam Ab26320 
KRAS 21 Mouse 1:500 Sigma-Aldrich WH0003845M1 
GAPDH 37 Mouse 1:20000 Sigma-Aldrich G8795 
Anti-Rabbit HRP-
linked 
- Goat 1:2000 Promega W401B 
Anti-Mouse HRP-
linked 
- Goat 1:4000 Promega W402B 
 
3.2.3. Total RNA Harvesting and Quantitative PCR of KRAS Steady-state Levels 
 Total RNA was extracted using the Thermo Scientific mirVana™ miRNA isolation kit 
using the manufacturer’s protocol. Treated cells were harvested after a 48-h treatment window. 
Cells were washed with 2 mL DPBS and 200 μL of Lysis buffer were added per well. Lysate (~600 
μL) was pooled together into a clean 1.5 mL Eppendorf tube and was vortexed gently. To the 
lysate, 1/10 x volume of Homogenate additive was added. The tube was mixed by inversion and 
left on ice for 10 min. Afterwards, 1 x volume of Acid-phenol: Chloroform solution was added. 
The Eppendorf was vortexed for 45 sec and centrifuged for 5 min at 10,000 x g (room temperature). 
The upper phase was transferred to a new Eppendorf and the volume was recorded. To the upper 
phase, 1.25 x volume of 100 % ethanol was added. The mixture was loaded onto the filter cartridge 
and was centrifuged at 10,000 x g for 15 sec. The flow-through was discarded and 700 μL of Wash 
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Solution #1 was added. The cartridge was centrifuged at 10,000 x g for 15 sec and the flow-through 
was discarded. The cartridge was then centrifuged after addition of 500 μL of Wash Solution #2/3 
and this process was repeated once more. Excess solvent was removed with a final centrifugation 
step (1 min, 10,000 x g) before the sample was eluted with 100 μL of 95°C nuclease-free H2O. 
RNA was quantified using the Thermo Scientific NanoDrop spectrophotometer.  
 RNA was cleaned using the Ambion DNA: free™ kit using the manufacturer’s protocol. 
RNA (1 μg, 8 μL) was added to 1 μL of 10 x DNase I buffer and 1 μL DNase I. The sample was 
incubated at 37 °C for 30 min. After incubation, 2 μL of Inactivating reagent was added and the 
sample was incubated at room temperature for 2 min. The sample was centrifuged at 10,000 x g 
for 1.5 min at room temperature. The supernatant was removed and the pellet was discarded. 
Following clean-up, cDNA was synthesized using BIO-RAD’s iScript™ cDNA synthesis kit. Each 
sample (1 μg in 10 μL) was added to 4 μL of 5 x Master Mix, 5 μL of nuclease-free H2O and 1 μL 
of reverse transcriptase in a new Eppendorf tube. The Master Mix contains a universal primer. The 
cDNA was synthesized using a thermocycler under the following conditions: 25°C for 5 min, 42 
°C for 30 min and finally 85 °C for 5 min. Following incubation, samples were prepared for 
quantitative PCR using Quantabio’s PerfeCTa SYBR Green Fast Mix kit. Each sample was 
prepared as the following mixtures: 5.3 μL nuclease-free H2O, 7.5 μL SYBR green master mix, 
0.6 μL forward primer (10 μM), 0.6 μL reverse primer (10 μM) and 1 μL cDNA. The primer 
sequences can be found in Table 3.2.2. 
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Table 3.2.2. Primer sequences for qPCR analysis of spiro-treated CRC cells. 
Name Annealing 
Temperature 
(°C) 
Forward Sequence Reverse Sequence 
KRAS 58 5’-CGA ATA TGA TCC AAC 
AAT AGA G-3’ 
5’- ATG TAC TGG TCC CTC 
ATT-3’ 
GAPDH 60 5’-GTC TTC ACC ACC ATG 
GAG AAG-3’ 
5’-AGT TGT CAT GGA TGA 
CCT TGG-3’ 
 
The samples were added to a 96-well qPCR plate (Axygen, California, USA). Control wells 
which did not contain primers were also added. Technical triplicates were performed for each 
reaction. The thermocycler used was the BIO-RAD iCycler and analysis was performed using the 
BIO-RAD iQ5 software. The thermocycler protocol starts with 3 min at 95 °C followed by 40 
cycles of 10 s at 95 °C and 30 s at 58 °C (KRAS) or 60 °C (GAPDH). A thermal melt curve was 
performed following data collection. The cycle threshold (Ct) values of each technical replicate 
was recorded and averaged. The averaged Ct for the target gene was subtracted from the Ct of the 
HKG to produce the ∆Ct value. The ∆Ct was then normalized with the DMSO control to produce 
the ∆∆Ct value. Lastly, the expression ratio was calculated by normalizing the treatment ∆∆Ct 
value with the DMSO ∆∆Ct value. 
3.2.4. MTT Assay Quantification of Cell Viability  
 The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay analyses 
were performed by Dr. Maggie Li. Cells were grown to 80 % confluency in T75 flasks, trypsinized 
and counted as indicated before. SW480 and HT29 cells were plated in Sarstedt 96-well cell culture 
plates at the concentration of 1500 cells/well and 2000 cells/well respectively and incubated 
overnight. Cells were then treated with compounds from 0 to 40 μM concentration (100 μL per 
well) and incubated for 48 h. Afterwards, 50 μL of MTT dye (1 mg/mL) was added to each well 
and the plate was incubated for 3 h at 37 °C. Live cells containing active mitochondrial reductase 
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causes reduction of the yellow-colored tetrazolium MTT dye to the purple-colored formazan 
product (Figure. 3.2.1.).  
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Reductase
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan
MTT Formazan  
Figure 3.2.1. Scheme for the reduction of MTT to the formazan form. 
 
The supernatant was removed and 100 μL of 100% DMSO was added to each well causing 
solubilization of formazan crystals. The plate was then read at 570 nm with the BioTek® Synergy 
2 plate reader. 
3.2.5. Flow Cytometry  
3.2.5.1. Apoptosis and Necrosis Detection 
 The BD Pharmingen™ PE Annexin V Apoptosis Detection kit was used for staining of 
cells for apoptosis and necrosis detection.  After treatment of cells at 24 and 44 h, cells were 
washed with 1 mL DPBS and trypsinized with 200 uL trypsin-EDTA (0.25 %). The digestion was 
stopped with the addition of 1 mL EMEM (10% FBS). Cells were transferred to a 1.5 mL 
Eppendorf tube and centrifuged at 400 x g for 5 min (RT). The supernatant was removed and the 
pellet was washed with 1 mL cold DPBS. Cells were counted manually as before. Cells were then 
resuspended in Binding Buffer (0.01M Hepes, 0.14M NaCl and 2.5 mM CaCl2; pH 7.4) at the 
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concentration of 1 x 106 cells/mL. Approximately 1 x 105 cells (100 μL) was transferred into a 5 
mL culture tube and stained with 5 μL of 7-aminoactinomycin-D (7-AAD) and 5 μL of Annexin-
V-PE (Figure. 3.2.2.). Annexin V-PE is a conjugation of the proteins, Annexin V and 
Phycoerythrin (PE). PE functions as the chromophore (structure not shown). Cells were incubated 
in the dark for 15 min at room temperature. Binding Buffer (400 μL) was added and cells were 
filtered before being separated and detected by the BD FACSMelody™ cell sorter. Unstained and 
single stain controls (7-AAD or Annexin V-PE) were also produced. Single stain for Annexin V-
PE follows the same protocol. The 7-AAD control has an extra freeze-thaw step. Approximately 
100 μL of cells were placed at -80°C for approximately 5 min. The cells were then thawed at 37 
°C and stained with 7-AAD using the previously described protocol. Data was processed using the 
FlowJo software package. 
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Figure 3.2.2. Structure of 7-Aminoactinomycin-D. 
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3.2.5.2. Analysis of Cell Cycle Population 
 Cells (5 x 105 cells/mL) in DPBS were acquired from the previous preparation described 
above and is instead, processed using the BD Cycletest™ Plus DNA Reagent Kit. The cells were 
pelleted at 400 x g for 5 min. The supernatant was removed and 250 μL of Solution A containing 
trypsin was added. The sample was incubated for 10 min at room temperature. Solution B (200 
μL), the trypsin inhibitor, was then added and the sample was incubated for another 10 min. Cold 
Solution C (200 μL), which contains propidium iodide (PI), was added (Figure. 3.2.3.). The tube 
was mixed and incubated in the dark on ice for 10 min. Cells were then detected with the BD 
FACSMelody™ and data was processed with FlowJo as before. 
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Figure 3.2.3. Structure of propidium iodide. 
 
3.3. Results and Discussion  
3.3.1. Fluorescence Enhancers and Quenchers Found in the Fluorescence Polarization 
Assay 
The fluorescence polarization assay technique was the first strategy for determining initial 
activity of synthesized mixtures. These mixtures were compared with the UNBC152-3 (7) with 
the goal of determining which compound exhibit favorable activity with reducing IMP-1 protein 
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binding with KRAS mRNA. Comparison of UNBC152-3 (7) with the crude batch of VLA9 (7, 
Section 2.2.2.) was performed first. As SPOPP (8) was hypothesized to be produced in the 1,3-
dipolar cycloaddition synthesis of UNBC152-3, the crude batches VLA25 (8/9) and VLA21 (8/9) 
were also included. Additional controls of ʟ-proline (5), 3 (VLA3) and acenaphthenequinone (4) 
were included to determine if the individual reactants had non-specific interactions with either 
IMP-1 protein or the KRAS RNA. Protein was set at 300 nM which represented 80 % maximal 
binding between IMP-1 and 10 nm KRAS RNA. Unsurprisingly, VLA3 (red), 
acenaphthenequinone (black) and ʟ-proline (violet) did not exhibit the ability to reduce the percent 
bound, even at 100 μM treatment (Figure. 3.3.1.). VLA9 (yellow) did not decrease the percent 
bound either. This result was surprising considering VLA9 (7) was suggested to contain all 3 
regioisomers of the expected product (7). Post-synthesis of VLA9 (7), the yellow colored solid 
was filtered and separated from the mother liquor (supernatant). The mother liquor (M. Liq) was 
dried and tested in the FP analysis. Interestingly, the M. Liq was able to reduce the percent bound 
of IMP-1 to KRAS mRNA. UNBC152-3 was able to reduce the percent bound to 63 %. Both 
UNBC152-3 and VLA9 contained presence of the unreacted reagent 3. From the results, it was 
hypothesized that the portions of the UNBC152-3 crude mixture which could lead to an interaction 
with either the protein or probe would be the minor products found in the early HPLC retention 
time points or SPOPP (8) as seen in section 2.2.4.1 (Figure. 2.2.4.1.).   
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Figure 3.3.1. Comparison of crude spiropyrrolizidine and dispiropiperazine compounds 
on the IMP-1-KRAS mRNA interaction. Protein used was 300 nm KH3to4 with 10 nm 
KRAS-FL probe.  Experiment performed in technical triplicate. 
 
VLA21 (8/9 blue) and VLA25 (8/9 purple) were found to reduce the percent bound to 55.3 
% and 45.3 % respectively which suggested that components of the mixture were able to interact 
with either the probe or the protein to reduce FP units. Purified portions of the 2-component 
reaction (Section 2.2.3) were prepared and analyzed by fluorescence polarization to determine 
which compound(s) was responsible for the in vitro activity. Additionally, the total fluorescence 
of the interaction (green bars) was monitored to determine any differences between 2 % DMSO 
control and treatment wells (Figure. 3.3.2.).  UNBC152-3 (7) and VLA9 (7) were included as 
positive and negative controls, respectively. For faster comparison purposes, compounds were 
tested at 100 μM instead of in a dose-dependent manner. UNBC152-3 (7) decreased the percent 
bound to 66.17 % but increased total fluorescence to 141 %.  VLA9 (7) did not decrease the percent 
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bound compared to the control but had the total fluorescence increased to 109 %. The change in 
total fluorescence compared to control can be problematic since FP relies on fluorescence as an 
output. One of the common criteria for excluding compounds as potential hits is the total 
fluorescence change.38 In the Shapiro article on IMP-1 inhibitors, candidates that increased total 
fluorescence by 30 % or more were marked as fluorophore enhancers and compounds which 
decreased the total by 30 % or more were marked as fluorophore quenchers. Both quenchers and 
enhancers are typically deemed as false positives and are excluded in subsequent analyses.38 
 
Figure 3.3.2. Comparison of purified SPOPP (8) and NP6A versus crude batches on the 
IMP-1-KRAS mRNA interaction. 60 nM KH1to4 was used in presence of 2 nM KRAS-FL 
probe. Compounds were treated at 100 µM concentration. Experiment was performed in 
technical triplicate. Error bars are standard deviation.  
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The FP data on UNBC152-3 (7) suggested presence of an enhancer due to the 41 % change 
in fluorescence. An interesting component in these reaction mixtures was NP4 which was a peak 
found in varying abundance in the HPLC traces of all crude batches. NP4 is the fluorescence 
compound seen under long wave UV in the TLC analysis of the crude mixtures in section 2.2.6.1. 
(Figure. 2.2.6.2.). The TLC-purified NP4 increased total fluorescence to 289 % and decreased the 
percent bound to 33 %; this suggested that one of the major causes of the FP unit decrease for 
crude batches was due to the presence of NP4 interfering with the assay. VLA159 (8/9) and 
VLA175 (8/9) were also found to have a greater than 30 % increase in total fluorescence. In 
contrast, analysis of purified SPOPP (8) and NP6A on the IMP-1-KRAS mRNA interaction 
revealed that the two dispiropiperazine compounds did not change percent bound or total 
fluorescence. This data indicated that neither SPOPP (8) nor NP6A truly inhibit the IMP-1-KRAS 
mRNA interaction. The F1 sample, VLA37-1, did reduce percent bound to 32 % but also decreased 
total fluorescence to 78 %. Since the decrease in total fluorescence is within the acceptable limits, 
additional F1 samples were analyzed. As compared to 2 % DMSO, all the F1 samples were able 
to decrease percent bound by varying amounts (Figure. 3.3.3.).  
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Figure 3.3.3. Effect of semi-purified F1 components on the IMP-1-KRAS mRNA 
interaction. 300 nM KH1to4 was analyzed in presence of 10 nM KRAS-FL. Compounds were 
treated at 100 µM. F1 components were purified from crude by FCC with C18 matrix (8 H2O: 
2 methanol: 4 acetonitrile: 0.25 acetic acid). Experiment was performed in technical triplicate. 
Error bars are standard error. 
 
The only two samples which were found to be within acceptable fluorescence bounds were 
VLB165-1 and HX31AB. From the data, it was hypothesized that some side products and/or 
intermediates within the F1 sample may collectively interact with either the IMP-1 protein or the 
KRAS RNA probe to decrease binding. Selective F1 samples were tested in colorectal cancer 
(CRC) cells to determine bioactivity. Since there can be a disparity between in vitro assay activity 
and bioactivity within a cellular environment, SPOPP (8) and NP6A were also investigated.  
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3.3.2. Effect of Inhibitors on KRAS Expression in CRC Cells 
3.3.2.1. Activity in SW480 
 SW480 CRC cells were first tested with the purified and crude forms of the 
spiropyrrolizidine derivatives. As a basis for comparison, treatment was kept to the 48 h time frame 
as previously described by Ms. Chuyi Wang.73 The compounds were initially tested at 10 μM 
concentration. UNBC152-3 (7) was kept as the positive control and was found to lower KRAS 
protein expression to 24 % when normalized against Thioredoxin (Figure. 3.3.4). VLA9 (7) was 
also able to reduce expression to 23 % and was the most potent at the time of testing for this 
particular trial. Some of the activity may be attributed to presence of 3 in both VLA9 (7) and 
UNBC152-3(7). The bioactivity of 3 was previously described by Dimmock et al. in the structural 
activity relationship (SAR) analysis of 2-arylidenebenzocycloalkones derivatives.75 Human Molt 
4/C8 and CEM T-lymphocytes cell lines were treated with 3 and the IC50 was found to be 36.8 ± 
1.3 and 25.4 ± 5.9 μM respectively. Purified SPOPP (8) and NP6A were also able to lower KRAS 
expression to 63 % and 26 % respectively. Since VLA159 (8/9) is a crude version of SPOPP (8), 
it was not surprising to see that it also lowered KRAS expression. The crude material, however, 
did contain more compounds and thus the combination was hypothesized to cause the increase in 
activity. As a semi-purified mixture, VLA37-1 lowered KRAS expression to 52 % but the effect 
was weaker than both VLA159 (8/9) and UNBC152-3 (7).   
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A 
 
B 
 
Figure 3.3.4. Effect of purified SPOPP (8) and NP6A on KRAS expression in SW480 CRC. 
(A) Cells were incubated with 10 µM concentration compounds for 48 h. (B) Normalized 
expression of KRAS against Thioredoxin and relative to DMSO control.  N = 1. 
 
The FP false positive, NP4, interestingly was able to reduce KRAS expression to 41 % 
which further complicates the analysis of the UNBC152-3 (7) puzzle. More F1 components were 
tested alongside NP6A to determine if it was reproducible (Figure. 3.3.5.). Compounds were 
treated at 20 μM to see a more pronounced reduction of KRAS expression. NP6A was found to 
lower KRAS expression to 68 % which was over 2-fold weaker than the previous trial. VLB188-
1 increased KRAS expression to 120 % while VLB189-1 lowered expression to 80 %. Treatment 
of AcQ (4) at 20 μM was able to reduce KRAS expression to 53 %. The sample was tested as a 
control due to its role as one of the reactants. A search on scientific literature indicated that 
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acenaphthenequinone has not been tested in SW480 before which made this the first reporting of 
its bioactivity in this cell line. VLB165-1 increased expression of KRAS to 141 %. UNBC142 was 
previously reported to have no activity in SW480 and was used as a negative control in this 
experiment.73 Due to the inconsistencies with the F1 activity, the subsequent Western blot analysis 
of the semi-crude material in HT29 was abandoned. The focus was also switched to analyzing 
SPOPP (8) since it was purified to 100 %. 
A 
 
B 
 
Figure 3.3.5. Effect of semi-purified F1 samples on KRAS expression in SW480 CRC. (A) 
Cells were incubated with 20 µM concentration compounds for 48 h. (B) Normalized expression 
of KRAS against thioredoxin and relative to DMSO control.  N = 1. 
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3.3.2.2. Activity on HT29 
Compounds were tested on HT29 at the 20 μM concentration. Treatment with SPOPP (8) 
was found to lower KRAS expression to 72 % (Figure. 3.3.6.). AcQ (4) had less of an effect and 
reduced expression to 82 %. The activity of AcQ (4) on HT29 has not been previously reported. 
Treatment with 3 (VLA3) was able to reduce KRAS expression to 51 %; this result was significant 
due to the compound’s presence in both the VLA9 (7) and UNBC152-3 (7) samples. Although 3 
was not able to reduce FP units in the fluorescence polarization assay, it was able to decrease 
expression of KRAS. The result suggested that 3 may have contributed to the biological activity 
of UNBC152-3 (7) in SW480 in both the current study and during the initial testing of this library 
hit by Ms. Chuyi Wang.  
A B 
 
 
 
 
Figure 3.3.6. Effect of SPOPP (8) and reagents on KRAS expression in HT29 CRC. (A) 
Cells were incubated with 20 µM concentration compounds for 48 h. (B) Normalized 
expression of KRAS against GAPDH and relative to DMSO control.   
 
Cells were treated twice more with SPOPP (8) to produce two other biological replicates. 
SPOPP (8) reduced expression to 65 % which was consistent with the previous finding (Figure. 
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3.3.7.). Similarly, AcQ (4) was still able to reduce expression again to 88 % which was a very 
consistent reduction. NP6A, however, increased expression to 165 % which was inconsistent with 
the SW480 results. UNBC168 was tested to see if it can also be used as a negative control but it 
seemly increased KRAS protein expression. 
A B 
 
 
 
Figure 3.3.7. Effect of SPOPP (8) and NP6A on KRAS expression in HT29 CRC. (A) Cells 
were incubated with 20 µM concentration compounds for 48 h. (B) Normalized expression of 
KRAS against GAPDH and relative to DMSO control.   
 
A third biological replicate confirmed the bioactivity of SPOPP (8) and AcQ (4); KRAS 
was found to be reduced to 76 % and 74 % respectively (Figure. 3.3.8.). NP6A increased KRAS 
to 148 % which was consistent with the prior trial. The western blot data was aggregated and the 
reduction of KRAS protein in HT29 cells post treatment with SPOPP (8) is statistically significant 
with a P value of 0.0013 (Figure. 3.3.9.).  
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A B 
 
 
 
Figure 3.3.8. Effect of SPOPP (8) and NP6A on KRAS expression in HT29 CRC. (A) Cells 
were incubated with 20 µM concentration compounds for 48 h. (B) Normalized expression of 
KRAS against GAPDH and relative to DMSO control.   
 
 
 
Figure 3.3.9. Aggregated western blot data for KRAS protein expression in compound-
treated HT29. Cells were incubated with 20 µM concentration compounds for 48 h. Statistical 
analysis was performed using ANOVA. N = 3. P = 0.0013. 
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Although KRAS can be reduced by treatment with SPOPP (8) and a select few F1 samples, 
it does not necessarily mean there is a reduction on cellular proliferation. Compounds were 
analyzed by the MTT assay to validate the impact on proliferation.  
3.3.3. Cell Viability Analysis of Compound-treated CRC Cells 
3.3.3.1. Proliferation in SW480 
 The MTT assay is a quick and useful method to determine cell viability. The MTT dye is 
a tetrazolium salt that is reduced in the mitochondria with Mitochondrial Reductase to produce the 
insoluble formazan form (Figure. 3.2.1.).81 Dye formation is then proportional to the amount of 
live cells present. The MTT trials were performed by Dr. Maggie Li. Cells were treated with 
compounds ranging from 0 to 40 μM concentration and the intensity of the formazan dye was 
analyzed as compared to 2 % DMSO control. Treatment of SW480 cells with SPOPP (8) led to 
reduced cell viability with an IC50 of 4.17 μM (Figure. 3.3.10.). 
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Figure 3.3.10. MTT assay analysis on SPOPP-treated SW480. Cells were treated using 
compounds ranging from 0 to 40 µM concentration. Cells were incubated for 48 h. Error bars 
are standard deviation. Experiment was performed in technical triplicate. N = 1.  
 
AcQ (4) also had a low IC50 of 4.78 μM. The results clearly showed that both SPOPP (8) 
and AcQ (4) are anti-proliferative to SW480 cells. Paradoxically, 3 did not reduce viability to the 
same level despite being able to reduce KRAS protein expression levels by 49 % (Figure. 3.3.6., 
Figure. 3.3.10.). This result suggested that KRAS expression is not necessarily correlated with cell 
proliferation. The results show at least one instance where a reduction of KRAS might not lead to 
a reduction of cell viability. HX152 (7) was the sample prepared by purification of the main peak 
in the crude UNBC152 (7) synthesized by Ms. Hooi Xian Lee (Section 2.2.2.). The peak was found 
at 6.9 min in the phenyl-hexyl analysis as previously described in Chapter 2. Interestingly, HX152 
(7) did not appear to have any significant effect on SW480 cell viability; therefore, one isomer of 
7 appears to be non-bioactive. F1 fractions isolated from crude batches of 8 were also analyzed. 
The rationale was to see if any side-products were able to collectively affect viability. Treatment 
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of the cells with VLB165-1, 159-1, 188-1 and 189-1 was able to lower viability with IC50 values 
close to AcQ (4) and SPOPP (8, Figure. 3.3.11.). 
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Figure 3.3.11. MTT assay analysis on F1 -treated SW480. Cells were treated with compounds 
ranging from 0 to 40 µM concentration. Cells were incubated for 48 h. Error bars are standard 
deviation. Experiment was performed in technical triplicate. N = 1. 
 
It is possible that multiple components of the F1 fractions were able to interact with IMP-
1 collectively to prevent KRAS mRNA association. The unbound KRAS mRNA would then be 
free to interact with endonucleases or miRNA leading to reduced KRAS protein and the 
subsequent decrease in proliferation. Alternatively, the components of F1 may interact with 
multiple effectors associated with growth pathways thus leading to proliferation decrease. Either 
scenario is possible but would still need to be validated. To test the IMP-1-KRAS mRNA 
interaction decrease, immuno-precipitation of endogenous CRC IMP-1 protein will have to be 
performed on F1-treated cells. From the analysis, there would be a decrease in KRAS mRNA that 
is associated with the precipitated protein as compared to DMSO control if the case is true.  
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3.3.3.2. Proliferation in HT29 
 Semi-purified F1 (188-1.1) derived from VLB188-1 was tested in HT29 to determine if 
purification was able to increase potency (Figure. 3.3.12.).  
 
Figure 3.3.12. MTT assay analysis of SPOPP (8) and semi-purified F1 on HT29. Cells were 
treated with compounds ranging from 0 to 40 µM concentration. Cells were incubated for 48 h. 
Error bars are standard deviation. Experiment was performed in technical triplicate. N = 1. 
 
After fractionation, the 188-1.1 did not display marked improvement versus the parent F1. 
Initially, cell viability decreased with a maximum treatment of 2.5 μM as compared to F1. 
Concentrations of 188-1.1 from 5 to 40 μM shared a similar decrease in cell viability.  The most 
potent compound tested was SPOPP (8), which had an IC50 of 6.76 μM; the potency was similar 
to that observed with SW480. Since SPOPP (8) was the most consistently bioactive compound, 
further testing was conducted and the pursuit of F1 was set aside.  Several other compounds have 
similar activity to SPOPP (8, Figure. 3.3.13.). AcQ (4), again, was effective on HT29 and had an 
IC50 of 8.51 μM. UNBC168, which was used as a negative control since it was another 1,3-dipolar 
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cycloaddition product utilizing 4 and 5 as precursors but was inactive in the FP assay, did not 
decrease viability.  
 
 
Figure 3.3.13. MTT assay analysis of SPOPP (8) and NP6A on HT29. Cells were treated 
with compounds ranging from 0 to 40 µM concentration. Cells were incubated for 48 h. Error 
bars are standard deviation. Experiment was performed in technical triplicate. N = 1. 
 
It has been previously reported that resveratrol, at a concentration  of 60 μM, decreases 
KRAS expression and cellular proliferation in HCT116 and SW480 CRC cell lines.82 In light of 
this information, resveratrol was used as a positive control in these experiments. Treatment with 
40 μM resveratrol decreased HT29 cell viability to approximately 60 %. Interestingly, crude VLA9 
(7) was able to reduce proliferation the most with an IC50 of 4.47 μM. VLA9 (7) contains both 3 
and 7. Since, by part, 3 and 6 did not have activity, it was hypothesized that the combination of all 
the reactants and products in VLA9 (7) led to the proliferation decrease seen in HT29. NP6A, on 
the other hand, only had modest activity in HT29.  
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3.3.4. Effect of SPOPP (8) on KRAS mRNA Levels in HT29 Cells 
Steady-state levels of KRAS mRNA was analyzed in SPOPP-treated HT29 cells as an 
initial step to determine the mechanism whereby SPOPP (8) decreases cell proliferation. A total 
of four biological replicates were conducted and cells were treated with 20 μM of each compound. 
The results pooled from four biological replicates showed that treatment with SPOPP (8), AcQ (4) 
and NP6A did not significantly change the steady-state levels of KRAS mRNA in HT29 cells 
(Figure. 3.3.14.).  
 
Figure 3.3.14. Analysis of KRAS mRNA steady-state levels in SPOPP-treated HT29 by 
quantitative PCR. Results were normalized to GAPDH. Biological replicates where N = 4. P 
= 0.5667. Statistical analysis by ANOVA. Error bars are standard error. 
 
Since the KRAS mRNA levels did not change while suppression of KRAS protein was 
observed, I hypothesize that SPOPP (8) acts at the level of translational repression on KRAS. 
There is a possibility that SPOPP (8) can increase miRNA leading to translational repression of 
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KRAS. In the Saud et al. paper on resveratrol and CRC, tumors resected from resveratrol-treated 
APCCKO/KRASmut mice contained a 67% increase of microRNA 96 (miR-96).82 The miR-96 was 
previously found to directly target the 3ʹ-UTR of the KRAS transcript in pancreatic cancer cells.83 
Microarray or RNA-seq analysis of SPOPP-treated HT29 and SW480 would have to be performed 
to determine global change for miRNA. Alternatively, qPCR can be performed as an inexpensive 
method if a subset of miRNAs, such as miR-96, were to be tested for.  
3.3.5. Investigating the Anti-proliferative Mechanism of SPOPP (8) in SW480 
3.3.5.1. Necrosis versus Apoptosis 
  Flow cytometry was used as an analytical tool to determine the differences between 
necrotic and apoptotic cell populations. The same technique was used to determine differences in 
the cell cycle. In brief, the machine can sort a cell population into single cell droplets using a 
buffered sheath fluid as the vehicle. The droplets pass by a laser which excites fluorophore-labeled 
cells and the subsequent emission is detected. The machine also detects the degree of forward 
(FSC) or side light scatter (SSC) as a low-resolution determinant of cell size and shape.  The 
commonly used stains to detect necrosis and apoptosis are 7-AAD and Annexin V-PE respectively. 
In the case of necrosis, the cell membrane becomes compromised and is permeable to large dyes. 
The 7-AAD can then enter the necrotic cell and intercalate with DNA.84 Annexin V-PE is used to 
stain for apoptotic cells.85 Normally phosphatidylserine (PS) is sequestered in the inner membrane 
of cells. During the early stages of apoptosis, PS flips to the outer membrane to signal phagocytes. 
Annexin V was proven to have high affinity to PS and thus if conjugated to a fluorophore, can act 
as a quick method of determining an apoptotic cell. To determine the difference between necrosis 
and apoptosis, cells were dual-stained with both 7-AAD and Annexin V-PE (Figure. 3.3.15.). 
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A                       DMSO 24 h B                       SPOPP 24 h 
  
C                       DMSO 44 h  D                       SPOPP 44 h 
  
Figure 3.3.15. Distinguishing mechanism of cellular death on SPOPP-treated SW480 cells 
using flow cytometry. (A) 2% DMSO, (B) 20 µM SPOPP, (C) 2% DMSO, (D) 20 µM SPOPP. 
7-Aminoactinomycin D (7-AAD) detects necrotic cells with permeated plasma membrane. 
Annexin V-PE (PE) detects apoptotic cells through binding with phosphatidylserine. Necrotic 
cells (Q1), Late Apoptosis (Q2), Early Apoptosis (Q3) and Live cells (Q4). 
 
The results were then plotted in a 2-dimensional histogram in order to visualize population 
differences as indicated by fluorescence intensity. As a control, 2 % DMSO-treated SW480 cells 
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were dual-stained and measured at 24 h. Most of the cellular population (91.4 %) were seen in 
quadrant 4 (Q4) which was set as the base-line level of fluorescence for non-specific interactions 
with 7-AAD and Annexin V-PE (Figure. 3.3.15A.). Necrotic cells (0.89 %) were found in quadrant 
1 (Q1) as indicated by higher levels of 7-AAD staining. Cells undergoing early apoptosis (2.72 %) 
as indicated by higher levels of Annexin V-PE were found in quadrant 3 (Q3). Quadrant 2 (Q2) 
was the region which indicated high levels of both stains and contained 5.08 % of the total cell 
population. SPOPP (8) treatment of cells at 24 h caused the cell population to move towards a 
more necrotic state (Figure. 3.3.3.15B.). Q4 contained 60.9 % of the cell population which was a 
reduction of 30.5 % as compared to the control. Q1 contained 28.5 % of the population which was 
a drastic increase. The results indicated that the cellular population was moving towards a necrotic 
state and will ultimately end in cellular death. Activation of necrosis was further reflected by the 
shift in position of highest cellular density (red color) when compared to the control. Early 
apoptosis was not seen since Q3 only had 2.34 % of the population which was comparable to 
control (2.72 %). Q2 contained 10.8% of the cell population which suggested an increase in either 
late apoptosis or dead cells. Necrotic cells were also present for the 44 h SPOPP (8) treatment 
(Figure. 3.3.15D.). Q1 contained 16.9 % of total cell population which was a decrease of 11.9 % 
as compared to the 24 h treatment. The decrease indicated that the peak activity of SPOPP (8) for 
inducing necrosis in SW480 was around 24 h. 
3.3.5.2. Cell Cycle Distribution  
 
 Differences in cell cycle stages for a population of cells can also be measured by flow 
cytometry. The common dye used to stain cells is propidium iodide (PI), which serves to 
stoichiometrically bind DNA through intercalation.86 In the procedure, trypsin was used to cause 
limited digestion of the plasma membrane leaving the nuclei intact. Ribonuclease A was used to 
116 
 
remove any RNA to prevent false positives. The sample was then stained with PI, filtered to 
remove aggregates and analyzed using the flow cytometer. Cells are normally in the G1 phase of 
the cell cycle and has a ploidy of 2N. A switch to the synthesis phase (S) would cause the 
production of new DNA in preparation of cellular division. At the end of S phase and the beginning 
of the G2/M checkpoint, the cells would have twice the amount of DNA (4N ploidy). Twice the 
DNA would lead to twice the fluorescence from PI. Cells were monitored at 18, 24 and 44 h and 
2 % DMSO was used as the control. Histograms were plotted as fluorescence intensity of PI vs 
cell counts. The approximation of cell cycle percentages was performed using the Watson model 
and was displayed as the violet-colored trace (Figure. 3.3.16.). Treatment of cells with 20 μM 
SPOPP (8) for 18 h led to an increase of the G2/M peak (green) to 15 % when compared to the 
control which was pre-dominantly at G1 as shown by the purple peak (Figure. 3.3.16A., Figure. 
3.3.16D.).  
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A                   18 h B                   24 h C                    44 h 
   
D                   18 h E                   24 h F                    44 h 
   
Figure 3.3.16. Cell cycle analysis of SPOPP-treated SW480 cells using flow cytometry. (A-
C) 2 % DMSO control. (D-F) 20 µM SPOPP treatment. Cells were stained with propidium 
iodide (PI) which intercalates DNA. Cell cycle approximation through the Watson model is 
outlined in violet. The color coding is as follows: blue for G1 phase, yellow for S phase and 
green for G2/M phase. 
 
At the 24 h mark, treatment with SPOPP caused a further shift in cell population at the G2/M phase 
to 38 % (Figure. 3.3.16E.). The activity was seen to decrease at 44 h since the G2/M peak was 
reduced to 7.8 % (Figure. 3.3.16F.). The result indicated the peak activity of SPOPP was around 
24 h which was congruent with the apoptosis analysis. Unfortunately, the analysis does not 
differentiate between cells at the G2 check point or cells in the Mitosis (M) phase. 
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Both would have a ploidy of 4N. From the results, SPOPP is proposed to be a G2/M inhibitor 
which leads to necrosis of cells. The importance of G2/M inhibitors will be further discussed. 
Table 3.3.1. Summary of cell cycle population percentages for SPOPP-treated SW480. 
Treatment Time  
(h) 
G1 Phase  
(%) 
S Phase  
(%) 
G2/M Phase  
(%) 
2 % DMSO 18 80.0 17.6 3.1 
 24 126.0 6.1 0.8 
 44 93.6 8.3 0.5 
20 µM SPOPP 18 66.0 16.8 15.0 
 24 55.0 10.5 38.1 
 44 81.1 11.3 7.8 
 
3.3.6. Summary 
 The search for an inhibitor of the IMP-1-KRAS mRNA interaction was not successful. 
Purified compounds (8 and NP6A) were not able to impact the interaction. Components of F1 were 
able to lower IMP-1 percent bound in the FP assay but further purifications resulted in decreased 
potency as determined by MTT assay; thus, the pursuit of further purifications of F1 was 
abandoned. From FP and WB analyses, it was suggested that the previous bioactivity of 
UNBC152-3 (7) was due to a mixture of fluorescent false positives and the presence of previously 
described bioactive compounds (3 & 4). However, this is the first reporting on the bioactivity of 3 
and 4 for SW480 and HT29 human colorectal cancer cells.  On a positive note, 8 was found to be 
a potent compound for decreasing cellular proliferation in SW480 and HT29. Since 8 did not 
impact the steady-state levels of KRAS mRNA for HT29, it was hypothesized that 8 may 
upregulate miRNA(s) to produce translational repression of KRAS protein. Additionally, 8 was 
able to arrest SW480 cells in the G2/M phase of the cell cycle and was found to reduce cellular 
proliferation through necrosis. The importance of G2/M inhibition and necrosis is further discussed 
in Chapter 4. 
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Chapter 4 
General Discussion 
4.1 Project Overview 
 IMP-1 is part of the VICKZ family of RNA binding proteins which serves in 
spatiotemporal regulation of mRNA during embryogenesis and is absent in adulthood.21 
Reappearance of IMP-1 in colorectal cancer was detected by Ross et al. in 2001, thus earning its 
status as an important oncofetal protein worth interrogating.32 Furthermore, IMP-1 was found to 
bind several important oncogenes such as MDR-1, CD44, βTrcp-1, c-Myc and KRAS.23,26,27,87 
Binding of the oncogenic transcripts further exacerbates the cancer condition due to IMP-1’s role 
in shielding mRNA targets from degradation by endoribonucleases.23 Of particular note is the 
KRAS signaling protein. Activation of KRAS through GTP binding causes signal transduction of 
the canonical growth pathways of MAPK and PI3K leading to growth and differentiation.7 The 
issue lies in the scenario of KRAS driven cancers such as colorectal cancer.50 KRAS is often 
mutated at the 12th amino acid position which changes the glycine to valine.52 The mutation causes 
KRAS to be switched on permanently leading to constitutive signaling of growth pathways and a 
poorer clinical outcome for patients.50 Mongroo et al. found that knockdown of IMP-1 by siRNA 
led to a 60 % decrease in KRAS protein levels and subsequent decrease in cell proliferation in 
colorectal cancer (CRC) cells.27 The study also showed that IMP-1 has high affinity to KRAS 
mRNA.  Such important findings led to the hypothesis that inhibition of IMP-1 could lead to its 
dissociation from KRAS mRNA. The naked KRAS mRNA is then subjected to degradation by 
endoribonuclease or be translationally repressed by miRNA. A previous graduate student in Dr. 
Lee’s lab, Ms. Chuyi Wang, screened a small library of 217 spiropyrrolizidine derivatives using 
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the fluorescence polarization (FP) method and found 2 candidates which inhibited the IMP-1-
KRAS mRNA interaction: UNBC143 and UNBC152 (7).73 UNBC152 (7) was found to be the best 
hit from the assay. Western blot (WB) analysis of UNBC152-treated SW480 colorectal cancer 
cells showed suppression of KRAS protein level. However, the second batch of UNBC152 (7) 
made by our collaborator did not show any bioactivity. Subsequently, a third batch (UNBC152-3, 
7) was synthesized which produced the most activity according to FP analysis. To determine the 
cause of the discrepancy between the three batches, a LC-MS scan was performed for purity 
analysis. The results showed that the three batches were not pure and may contain isomers of the 
predicted structure. The goal of this investigation was to synthesize the UNBC152 (7) molecule(s) 
in-house according to the collaborator’s protocol and to determine the molecule responsible for: 
(i) inhibition of IMP-1-KRAS RNA interaction as determined but FP analysis, and (ii) suppression 
of KRAS expression as determined by Western blot analysis. The focus of this investigation was 
on the purification of the compounds and assessing their potential biological activity. This study 
was not meant to focus on the organic synthesis of UNBC152 (7) and its related compounds.   
4.2 Synthesis of Spiropyrrolidine Derivatives and the Focus on SPOPP (8) 
 Synthesis of the starting reagent, (2E)-2-(2-bromobenzylidene)-1-indanone (3) was a 
necessary step to produce the dipolarophile required for the 1,3-dipolar cycloaddition product of 
UNBC152-3 (7). The cycloaddition began after in situ generation of the azomethine ylide (6) 
produced by the decarboxylative reaction between acenaphthenequinone (4) and ʟ-proline (5). The 
azomethine ylide (6) formed the 1,3-dipole and fused with 3 in a concerted motion to form the 
proposed cycloproduct in UNBC152 (7). The crude batch was named VLA9 (7). However, as 
reported by Haddad et al. in 2015, two ylide intermediates can cyclize together to form the fused 
piperazines 8 and 9 as side-products of the main 1,3-dipolar cycloaddition reaction.77 Originally, 
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8/9 (VLA25) was synthesized as a control to test side-by-side with UNBC152-3 (7). At the initial 
stages of the project, HPLC-MS was not available, and I had no access to higher detailed analyses. 
At that time, the only information used was the TLC analysis of both UNBC152-3 (7) and the 
crude batch of 8/9 (VLA25).  TLC comparison between crude UNBC152-3 (7) and VLA25 (8/9) 
revealed a similar tailing pattern on normal phase TLC from 0 to 0.27 Rf (Figure. 2.2.3.3.). VLA9 
(7) did not have this tailing pattern but contained 3 other spots in common with UNBC152-3 (7). 
Given this information, it was hypothesized that compound(s) that exhibited bioactivity on FP and 
WB analyses were present within the tailing portion of the TLC. Due to the aforementioned 
information and the simpler reaction in terms of reagent usage, the focus was then shifted to the 
synthesis and purification of 8 (SPOPP). In summary, prior to the installation of the HPLC-MS, 
the preliminary work was primarily guided by results from TLC analysis.  
4.3 HPLC-MS Analyses of SPOPP (8) and UNBC152-3 (7) 
 With installation of the HPLC-MS at UNBC and hence its usage in this investigation, more 
valuable information was gained from the various synthesized batches of both 7 and 8. UNBC152-
3 (7) contained 3 major peaks and 3 minor peaks whereas the batched synthesized in house (7, 
VLA9) contained 3 major peaks and 2 minor peaks (Figure. 2.2.4.1.). The mass spectrophotometer 
used functioned by the electrospray ionization principle. Ionizable functional groups were 
protonated using 0.1 % formic acid and was detected on the MS as having a mass one Dalton larger 
than original due to the additional proton.  Following MS analysis, it was found that major peaks 
from 7.1 min and onwards corresponded to the predicted synthesized product (534 Da) as seen by 
the m/z ratio of 535 (Figure. 2.2.4.2.). Due to the physical delay between the variable wavelength 
detector (VWD) and the MS, there was an approximate 0.2 min retention time difference between 
the peak seen on VWD and the mass peak seen on MS. UNBC152-3 (7) contained two peaks 
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related to the cycloaddition product and one peak related to the starting reagent 3 (Figure. 2.2.4.1.). 
The VLA9 (7) sample contained 3 products (6.6, 7.6 and 9.1 min) and the presence of 3. The 
potential for the creation of three spiropyrrolizidine isomers in the 1,3-dipolar cycloaddition was 
previously reported by Haddad et al.77 The azomethine ylide formation between 4 and 5 can 
interconvert between the W-shape and the S-shape during the in situ reaction (Figure. 2.2.3.1). The 
dipolaraphile 3 can then interact with either the W-shape or the S-shaped form to produce 2 
different regioisomers. The minimum reaction time to produce the heterocycle was reported to be 
0.5 h, however, extension of the reaction time towards 24 h resulted in the creation of a third 
regioisomer. Creation of the third regioisomer was hypothesized to be due to a retro-1,3-dipolar 
cycloaddition and subsequent cycloreversion.77 Since VLA9 (7) contained three peaks of the 534 
mass, it was hypothesized that main two regioisomers were formed through the main reaction. The 
third product would then be formed by the cycloreversion mechanism. Conversely the UNBC152-
3 (7) only contained two of the peaks related to the product and it was hypothesized that the 
cycloreversion did not occur. Bioactivity comparison on FP between UNBC152-3 (7) and VLA9 
(7) was prioritized first. Structural elucidation of the three isomers was postponed. The rationale 
for this choice was to favor the search for the biologically active molecule using the FP screen. 
The goal was to determine the sole inhibitor of the IMP-1-KRAS mRNA interaction within the 
UNBC152-3 (7) mixture. If, as a collective, VLA9 (7) did not have activity based on FP, then there 
would not be any need to characterize the three regioisomers. This was especially true since the 
compounds were tested at concentrations of 100 μM. At that concentration, even minor peaks 
within the mixture would be abundant enough for testing purposes. If any component within the 
mixture was bioactive, it should then interact with IMP-1. The UNBC152-3 (7) mixture did contain 
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other early retention peaks from 0 to 3.7 min in the HPLC analysis (Figure. 2.2.4.1.). The peaks 
were hypothesized to be other side-products or intermediates of the reaction.  
The crude batch of SPOPP (VLA37, 8/9) was analyzed by HPLC using the same column 
and solvent system as the UNBC152-3 (7) analysis to search for similarly retained peaks. VLA37 
(8/9) also contained early retention time peaks from 0 to 3.8 min (Figure. 2.2.4.5A.). Of particular 
note was the peak at 3.7 min that was shared between UNBC152-3 (7) and the crude batch of 
SPOPP (8). The peak was named NP4 due to the region of the TLC where it was found on. The 
compound was a rather distinct yellow-looking spot when viewed using a UV transilluminator at 
320 nm (Figure. 2.2.6.1.). VLA37 (8/9) had four peaks located from 7.6 to 10.2 min on the VWD 
trace (Figure. 2.2.4.5.). All four peaks ionized to a mass of 471 m/z after protonation with 0.1% 
formic acid. In their paper, Haddad et al. only reported the generation of SPOPP (8) and 9 from 
their reaction sequence.77 Formation of the other two regioisomers, 8ʹ and 9ʹ, was deemed to be 
unfavorable due to steric factors between the naphthalene ring of one ylide and the pyrrolidine ring 
of the other ylide (Figure. 2.2.3.1.). Since the four peaks are separated by a minimum of 0.7 min 
by the phenyl-hexyl column as visualized by the VWD chromatogram, the retention time is far 
apart enough to conclude that all four peaks were different entities from each other (Figure. 
2.2.4.5.). The results indicated that all four possible isomers (SPOPP, 8ʹ, 9 and 9ʹ) were generated 
in the VLA37 (8/9) batch. It was also found that increasing the temperature in the synthesis of 
SPOPP (8) from 35 °C to 55 °C favored the production of the peak at 7.3 min and reduced the 
relative levels of side-products (0 to 3.7 min) (Figure. 2.2.4.7.). The rationale for this experiment 
was to determine the optimal temperature to produce SPOPP (8) which was approximately 55 °C. 
To date, there have been no other reports of the time and temperature dependencies in the creation 
of the fused piperazines 8 & 9.  
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4.4 Purification and Identification of the Fused Piperazines, SPOPP (8) and NP6A 
 As a comparison with UNBC152-3 (7) and VLA9 (7), SPOPP (8), as well as several other 
components of the reaction mixture were purified. The initial step was to purify the two fused 
piperazines as reported by Haddad et al. for use as controls.77 In their article, SPOPP (8) was 
reported as an orange-colored compound, and 9 as a yellow-colored compound. VLB133 (8/9) was 
used as the purification material due to the higher amount of product peaks relative to side-products 
(Figure. 2.2.4.7.) observed through HPLC analysis. Indeed, an orange and a yellow-colored band 
did appear from elution on a column packed with normal phase matrix. The yellow-colored band 
was named NP6A. It was hypothesized that NP6A was 9 but NMR analysis was not conducted at 
the time to prove the case. Unfortunately, the yield of both SPOPP (8) and NP6A was low. The 
yield of both compounds was further reduced upon HPLC purification. The reported benefits of 
cycloadditions are mild reaction conditions, ease of synthesis and highly functionalized isomers.77 
However, the benefits were balanced out by the difficulty of purification and the low yields. Due 
to the low abundance of the two isomers that were similar to SPOPP (8) and NP6A as indicated 
by the peaks retained from 7 to 10 min on VWD chromatogram, they were not pursued in terms 
of purification (Figure. 2.2.4.7.). Further enhancement of yields for 8 and 9 might be aided by 
microwave-assisted synthesis as reported by Bashiardes et al. in their analysis of synthesis 
conditions for the [3+2] cycloaddition of azomethine ylides.88  The microwave increased yields of 
the major products for most cases by greater than 5 %. SPOPP was confirmed to be 8 by comparing 
1H-NMR spectra obtained to what was reported in literature.77 NP6A, however, did not match the 
spectra of 9 in the literature due to the shift in the peak from 4.0 ppm to 4.88 ppm and the more 
over-lapping peaks in the aromatic region (Figure. 2.2.7.7., Figure. 2.2.7.8.). The aliphatic region 
of the 13C-NMR was also missing a peak compared to 9 (Figure. 2.2.7.9., Figure. 2.2.7.10.). 
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According to the spectra, NP6A was more symmetrical than what Haddad et al. reported for 8 and 
9. Higher resolution spectra of NP6A will have to be performed in order to elucidate the structure 
of NP6A. X-ray diffraction may also be required since Haddad et al. required the additional 
technique to structurally elucidate the various regioisomers reported in the paper.77 
4.5 Finding Inhibitors of the IMP-1-KRAS Interaction by Fluorescence Polarization Assay 
  At this time, an IMP-1-KRAS mRNA inhibitor does not exist in the literature. Ms. Chuyi 
Wang performed a preliminary screen of 217 spiropyrrolizidine derivatives on the interaction  but 
a vast majority of the compounds were reported to be auto-fluorescent.73 NP4 was one of the auto-
fluorescent compounds discovered during the analysis of UNBC152-3 (7) and SPOPP (8). 
Although it decreased the percent bound between IMP-1 and the KRAS-FL probe to 33 %, it 
enhanced total fluorescence to 289 % thus suggesting it as a likely false positive (Figure. 3.3.2.). 
NP4 was hypothesized to be present in several other compounds of the library since this particular 
series required the same azomethine ylide for the synthesis. UNBC152-3 (7) was proven to contain 
the NP4 compound; thus, its activity as a mixture was overestimated using this technique. To add 
further to this complexity, the F1 components of crude SPOPP (8) were also able to reduce FP 
units (Figure. 3.3.3.). UNBC152-3 (7) and SPOPP (8) had similar early retention time peaks in the 
HPLC trace. Since both compounds required 4 and 5 as starting reagents, it is hypothesized that 
most of the side-products were the same.  Therefore, the original FP activity of UNBC152-3 (7) 
was attributed to the presence of the side-products rather than the main products. The conclusion 
was further supported by the fact that VLA9 (7), which contained all three regioisomers of 
UNBC152-3 (7) and the starting reagent 3 but did not affect the IMP-1-KRAS mRNA interaction 
(Figure. 3.3.2.). Both the purified SPOPP (8) and NP6A did not reduce the binding of IMP-1 to 
KRAS-FL. From the results, there was no singular molecular species found which was able to 
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affect IMP-1 binding. Bioactivity from pure compounds derived in this study was then attributed 
to a mechanism other than inhibition of the IMP-1-KRAS mRNA binding. The development of 
small molecular inhibitors of IMP-1 is a new field. Thus far, only Shapiro has discovered a 
molecule which can target the IMP-1-c-Myc mRNA interaction.38 However, their reporting did 
not include supplementary information describing the purity of the compound. Purification of the 
lead compound remains an integral step of the process. As found in the purification and analysis 
of SPOPP (8), the side products alone (F1) lead to favorable activity in the FP assay. Evidence of 
purity in the form of 1H-NMR, mass spectrophotometry and HPLC chromatogram should remain 
as part of the proof; this would give confidence to researchers that the activity was due to a singular 
entity and not by a collection of compounds/side-products. 
Finding inhibitors of IMP-1, in general, is a monumental task. IMP-1 can recognize many 
mRNA substrates as shown previously for the binding assays of βTrcp1, CD44, c-Myc, MDR1 
and KRAS.20,23,25,26 The lack of a consensus sequence is both problematic and beneficial. From 
those studies, it is difficult to ascertain the true binding surface of IMP-1 that is essential for 
recognizing a specific RNA. Concurrently, the lack of a consensus sequence lends credence to the 
idea of a substrate-specific IMP-1 inhibitor. This is further supported by the fact that IMP-1 is 
suggested to recognize both sequence and secondary structure of RNA.20 The search for an IMP-
1 inhibitor can be continued for this particular study by soaking an IMP-1 crystal with the F1 
components. Chao et al. were able to produce a crystal of the truncated form of  IMP-1 which only 
contained the KH3 and KH4 domains.19 Soaking the IMP-1 crystal with F1 and usage of X-ray 
diffraction could determine which molecular components were able to associate with IMP-1. 
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4.6 Reduction of KRAS Expression in CRC 
 The goal of finding an inhibitor for the IMP-1-KRAS mRNA interaction was not 
successful. However, analysis of SW480 and HT29 human colorectal cancer cells after treatment 
with the spiropyrrolizidine and piperazine derivatives still resulted in reduction of KRAS protein 
expression. UNBC152-3 (7) and VLA9 (7) both reduced KRAS expression in SW480 (Figure. 
3.3.4.). The rationale for the biological activity was suggested to be due to the presence of reactant 
3 and 4 in both samples. Interestingly, even though 3 can reduce KRAS expression, it did not affect 
cellular proliferation as indicated by the MTT assay (Figure. 3.3.6., Figure. 3.3.10.). Reactant 4 
was able to reduce both KRAS protein expression and cellular proliferation in SW480 (Figure. 
3.3.5., Figure. 3.3.10.). From the results, it was hypothesized that the biological activity of 
UNBC152-3 (7), as previously found by Ms. Chuyi Wang, could be overreported due to the 
presence of 3, 4 and perhaps trace levels of 8.73 The conclusion was further supported by the fact 
that HX152 (7), which is the dominant product purified from the 1,3-dipolar cycloaddition reaction 
of UNBC152-3 (7), did not affect cellular proliferation of SW480 (Figure. 3.3.10.). The side-
products of UNBC152-3 (7) were also hypothesized to contribute to the overall biological activity 
of crude 8, since F1 was able to reduce both KRAS expression and cellular proliferation (Figure. 
3.3.5., Figure. 3.3.11.). The only remaining component of UNBC152-3 (7) that was not analyzed 
was a pure form of the secondary regioisomer found within the mixture. Focus was switched to 
characterizing the bioactivity of SPOPP (8). At the time, SPOPP (8) was a purified molecule and 
it was unlikely that the low-abundance secondary regioisomer was able to impact the IMP-1-
KRAS mRNA binding. SPOPP (8) was consistently able to reduce KRAS protein expression levels 
in both SW480 and HT29. Cellular proliferation was also confirmed to decrease upon SPOPP (8) 
treatment as indicated by the MTT assay. Since SPOPP (8) does not interrupt the IMP-1-KRAS 
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mRNA interaction as indicated by the FP results and does not affect KRAS mRNA steady-state 
levels, a different mechanism would be occurring (Figure. 3.3.2., Figure. 3.3.14.). It is 
hypothesized that treatment with SPOPP (8) increased a miRNA. The miRNA would then bind to 
the 3’ UTR of the KRAS transcript to produce translational inhibition of KRAS protein. There are 
miRNA candidates that were previously found to target the 3’UTR of KRAS such as miR-143 and 
miR-96.55,82 The mechanism for the repression is due to the miRNA binding to the 3’UTR regions 
where regulatory proteins normally interact.89 Validation on the increase of a specific miRNA can 
be performed using qPCR. However, if the miRNA is novel, RNAseq would have to be performed 
to determine global RNA level changes upon SPOPP (8) treatment.90 Validation of the novel 
miRNA can be performed through the use of a luciferase reporter assay.55 
4.7 SPOPP (8) Induces Cellular Death through Necrosis 
 As indicated by the MTT assay, treatment of cells with SPOPP (8) reduced cellular 
proliferation (Figure. 3.3.10.). The IC50 was found to be 4.17 μM. To characterize the mode of 
reduced proliferation, flow cytometry was used to discern between apoptosis and necrosis. Dual 
staining with 7-AAD and Annexin V-PE determined which cells were undergoing necrosis and 
apoptosis respectively. During necrosis, the cell membrane is permeabilized and the 7-AAD can 
enter the cells to then intercalate with DNA.84 Annexin V-PE detects apoptosis through the binding 
of cell-surface exposed phosphatidylserine which is normally sequestered in the inner membrane 
for normal cells.85   Treatment of cells with SPOPP (8) for 24 h revealed  a ~27 % increase in 
necrotic cells as indicated in Q1 by the increase in 7-AAD fluorescence as compared to the 2 % 
DMSO control (Figure. 3.3.15B.). The necrosis pathway was further supported by the upward 
movement of the cell population from Q4 to Q1 as compared to control and the lack of Annexin 
V-PE staining in Q3. Furthermore, maximal activity of SPOPP (8) was indicated to occur around 
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24 h which was evidenced by the 11.6 % reduction of cell population in Q1 as compared to 24 h 
(Figure. 3.3.15.). Although necrosis was classically known as an uncontrolled cellular process, 
Chan et al. found the process can be regulated.91 SPOPP (8) may act through the process of 
programmed necrosis (necroptosis).  Necroptosis is induced through the activation of the protein 
serine/threonine kinase receptor interacting protein 1 (RIP1) by receptor interacting protein 3 
(RIP3).92 RIP1 and RIP3 forms a complex (complex II) with Fas-associated protein with death 
domain (FADD) and mixed lineage kinase domain-like protein (MLKL).93,94 MLKL is then 
recruited to the plasma membrane due to the positively charged residues in the four-helical 
bundle domain (4HBD) of the N-terminal domain region.95 Oligomerization of MLKL occurs 
through 4HBD interactions leading to pore creation and permeabilization of the plasma 
membrane. The loss in osmotic pressure and cellular contents causes cell death, thus marking 
the end of the necroptosis pathway. Necrosis is a pro-inflammatory process due to its release of 
High mobility group 1 (HMGB1) protein.96 HMGB1 release into the tumor microenvironment 
causes recruitment and maturation of dendritic cells (DC).97 As part of the immune response, 
DC causes activation of CD8+ T cell lymphocytes which leads to anti-tumor immunity. 
Although treatment of CRC with SPOPP causes necrosis, the resultant activation of DC and 
recruitment of T cells would be highly beneficial. CRC have been known to evade immune 
surveillance with disease progression as marked by the decrease in T cells.98 However, proving 
the relationship between SPOPP-treated CRC and activation of CD8+ T cells would require an 
in vivo mouse model of CRC. Confirmation of necroptosis instead of uncontrolled necrosis can 
be found through dual treatment of CRC with SPOPP (8) and necrosulfonamide.94 
Necrosulfonamide was found to inhibit MLKL and prevent necrosis. Alternatively, necrostatin-
1 could be used to inhibit RIP1 which would also result in the prevention of necrosis.92 
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4.8 G2/M Inhibition by SPOPP (8)  
 Results from the flow cytometry analyses of cell cycle populations also rationalized the 
decrease in cell proliferation that was first indicated by MTT. Treatment of cells with SPOPP (8) 
for 24 h caused a noticeable increase in the G2/M cell population (38.1 %) as compared to 2 % 
DMSO control (Figure. 3.3.16.).  The maximal activity of SPOPP (8) was found to be at 24 h, 
since the G2/M population for the 44-h treatment down to 7.8 %. The percentages of the cell cycle 
population were estimated using the Watson model through the FlowJo software. Since PI staining 
was only able to measure DNA content, it cannot discern between cells at the G2 checkpoint and 
cells in mitosis. The ability of SPOPP (8) to halt the cell cycle combats one of the main hallmarks 
of cancer: resistance to anti-apoptotic signals.99 SPOPP (8) could either halt cells at the G2 phase 
or the mitosis phase of the cell cycle. The G2 checkpoint serves to detect aberrations in DNA before 
the commitment into mitosis and will halt the cell cycle through activation of checkpoint kinase 1 
(Chk1).100 Piperazine derivatives have been shown to generate reactive oxygen species (ROS) 
within cells.101–103 SPOPP (8) can potentially generate ROS sufficient enough to cause DNA 
damage leading to G2/M arrest.103 Regardless of the mechanism, G2/M inhibition by SPOPP (8) 
could be beneficial as a therapy. G2/M arrest and resultant radiosensitivity in CRC was previously 
shown by Jeong et al. through treatment with metformin.104 In light of this information, SPOPP 
(8) could act as a radiosensitizer for CRC.  
4.9 Concluding Remarks 
  In the investigation to determine the reason for the previously reported bioactivity of 
UNBC152-3 (7), it was found that the mixture contained both previously reported bioactive 
compounds and compounds which produced a false positive in the FP assay. Furthermore, a 
collection of potential side-products in the F1 fraction of the crude mixture was suggested to inhibit 
131 
 
the IMP-1-KRAS mRNA interaction, but the result may be non-specific. Co-crystallization of the 
F1 components with the KH3to4 crystal may elucidate potential binding surfaces within the two 
domains. While conducting research and syntheses for the 1,3-dipolar cycloaddition of UNBC152-
3 (7), the molecule SPOPP (8) was synthesized as a control. Although SPOPP (8) was not the 
original focus, preliminary TLC data led into the direction of synthesizing and purifying SPOPP 
(8). SPOPP (8) does not inhibit the IMP-1-KRAS mRNA interaction, however, it clearly 
suppresses KRAS protein expression in human colorectal cancer cells. I hypothesize that SPOPP 
(8) may increase miRNA(s) leading to translational repression of KRAS protein. The common 
issue with cancer progression is the cellular resistance to apoptosis and the ability to evade immune 
surveillance. Activation of necrosis/necroptosis by SPOPP (8) may counteract both issues and 
present a viable therapeutic approach. Inhibition of the cell cycle at G2/M may also aid in the 
radiosensitization of CRC. The bioactivity of SPOPP (8) has not been reported in literature and 
thus the work presented herein represents novel activity of SPOPP (8) in CRC. 
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